ATE102631T1 - Klonierung von immunglobulin sequenzen aus den variabelen domaenen. - Google Patents

Klonierung von immunglobulin sequenzen aus den variabelen domaenen.

Info

Publication number
ATE102631T1
ATE102631T1 AT89311731T AT89311731T ATE102631T1 AT E102631 T1 ATE102631 T1 AT E102631T1 AT 89311731 T AT89311731 T AT 89311731T AT 89311731 T AT89311731 T AT 89311731T AT E102631 T1 ATE102631 T1 AT E102631T1
Authority
AT
Austria
Prior art keywords
cloning
ligands
variable domains
receptors
immunoglobulin sequences
Prior art date
Application number
AT89311731T
Other languages
English (en)
Inventor
Gregory Paul Winter
Detlef Guessow
Elizabeth Sally Ward
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27562806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE102631(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888826444A external-priority patent/GB8826444D0/en
Priority claimed from GB898906034A external-priority patent/GB8906034D0/en
Priority claimed from GB898909217A external-priority patent/GB8909217D0/en
Priority claimed from GB898911047A external-priority patent/GB8911047D0/en
Priority claimed from GB898912652A external-priority patent/GB8912652D0/en
Priority claimed from GB898913900A external-priority patent/GB8913900D0/en
Priority claimed from GB898918543A external-priority patent/GB8918543D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of ATE102631T1 publication Critical patent/ATE102631T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT89311731T 1988-11-11 1989-11-13 Klonierung von immunglobulin sequenzen aus den variabelen domaenen. ATE102631T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB888826444A GB8826444D0 (en) 1988-11-11 1988-11-11 Cloning immunoglobulin variable domains for expression by polymerase chain reaction
GB898906034A GB8906034D0 (en) 1989-03-16 1989-03-16 Recombinant dna method
GB898909217A GB8909217D0 (en) 1989-04-22 1989-04-22 Antibody binding
GB898911047A GB8911047D0 (en) 1989-05-15 1989-05-15 Antibody binding
GB898912652A GB8912652D0 (en) 1989-06-02 1989-06-02 Antibody binding
GB898913900A GB8913900D0 (en) 1989-06-16 1989-06-16 Antibody binding
GB898918543A GB8918543D0 (en) 1989-08-15 1989-08-15 Antibody binding
EP89311731A EP0368684B2 (de) 1988-11-11 1989-11-13 Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.

Publications (1)

Publication Number Publication Date
ATE102631T1 true ATE102631T1 (de) 1994-03-15

Family

ID=27562806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89311731T ATE102631T1 (de) 1988-11-11 1989-11-13 Klonierung von immunglobulin sequenzen aus den variabelen domaenen.

Country Status (13)

Country Link
US (5) US6248516B1 (de)
EP (1) EP0368684B2 (de)
JP (1) JP2919890B2 (de)
KR (1) KR0184860B1 (de)
AT (1) ATE102631T1 (de)
AU (1) AU634186B2 (de)
CA (1) CA2002868C (de)
DE (1) DE68913658T3 (de)
DK (1) DK175392B1 (de)
ES (1) ES2052027T5 (de)
FI (1) FI903489A0 (de)
NO (1) NO903059L (de)
WO (1) WO1990005144A1 (de)

Families Citing this family (1876)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
EP0368684B2 (de) 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2006878A1 (en) * 1988-12-29 1990-06-29 John D. Rodwell Molecular recognition units
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US5602015A (en) * 1989-04-25 1997-02-11 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US6048717A (en) * 1989-04-25 2000-04-11 Igen International, Inc. Inhibitors of catalytic antibodies
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
US5658753A (en) * 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
US5599538A (en) * 1989-04-25 1997-02-04 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US5231015A (en) * 1989-10-18 1993-07-27 Eastman Kodak Company Methods of extracting nucleic acids and pcr amplification without using a proteolytic enzyme
US6274324B1 (en) 1989-12-01 2001-08-14 Unilever Patent Holdings B.V. Specific binding reagent comprising a variable domain protein linked to a support or tracer
GB8928501D0 (en) * 1989-12-18 1990-02-21 Unilever Plc Reagents
DE59109273D1 (de) * 1990-02-01 2010-01-07 Siemens Healthcare Diagnostics Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
DE4033120A1 (de) * 1990-10-18 1992-04-23 Boehringer Mannheim Gmbh Verfahren zur herstellung von chimaeren antikoerpern
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU1025692A (en) * 1991-02-06 1992-08-13 Ciba-Geigy Ag Novel chimeric antiidiotypic monoclonal antibodies
CA2081028C (en) * 1991-03-12 1999-12-14 Barbara P. Wallner Cd2 binding domain of lymphocyte function associated antigen 3
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
DK0580737T3 (da) * 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5962255A (en) * 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (de) 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
DE69233408T2 (de) * 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE4142077A1 (de) * 1991-12-19 1993-06-24 Boehringer Mannheim Gmbh Verfahren zur expression rekombinanter antikoerper
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993022332A2 (en) * 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
GB9216983D0 (en) * 1992-08-11 1992-09-23 Unilever Plc Polypeptide production
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
PT1231268E (pt) * 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
DK0898618T3 (da) * 1996-05-10 2008-02-25 Novozymes As Fremgangsmåde til tilvejebringelse af hidtil ukendte DNA-sekvenser
ATE391183T1 (de) 1996-08-19 2008-04-15 Morphosys Ip Gmbh Vektoren/dna-sequenzen aus humanen kombinatorischen antikörper-bibliotheken
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
EP1965213A3 (de) 1998-02-04 2009-07-15 Invitrogen Corporation Microarrays und ihre Verwendungen
WO1999058655A2 (en) 1998-05-13 1999-11-18 Diversys Limited Phage display selection system for folded proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US7297478B1 (en) 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
CA2398466A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US8101553B1 (en) 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
EP2341075A1 (de) 2000-03-01 2011-07-06 MedImmune, LLC Anti-rsv-f-protein-antikörper
EP2199393B1 (de) * 2000-04-17 2012-10-31 Dyax Corp. Verfahren zur Einrichtung von Bibliotheken für genetische Verpackungen unterschiedlicher Familien von Peptiden
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP1340088B1 (de) 2000-11-17 2007-01-17 University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2002230734A1 (en) 2000-12-11 2002-06-24 Alexion Pharmaceuticals, Inc. Nested oligonucleotides containing hairpin for nucleic acid amplification
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
ES2430857T3 (es) 2000-12-18 2013-11-22 Dyax Corp. Bibliotecas focalizadas de paquetes genéticos
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
EP1370292A1 (de) 2001-01-31 2003-12-17 Idec Pharmaceuticals Corporation Verwendung von cd23 antagonisten zur behandlung von neoplastischen erkrankungen
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2454618C (en) 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CA2763913C (en) 2001-08-10 2014-10-28 Aberdeen University Antigen binding domains
AU2002332598A1 (en) * 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
US20040005709A1 (en) * 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
EP1456237A2 (de) * 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Methode zur klonierung von sequenzen aus den variablen domänen
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
EP2508596B1 (de) 2002-02-21 2015-08-12 Institute Of Virology MN/CA-IX-spezifische, von MN/CA-IX-defizienten Mäusen erzeugte monoklonale Antikörper und Verwendungsverfahren
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7135310B2 (en) 2002-04-24 2006-11-14 The Regents Of The University Of California Method to amplify variable sequences without imposing primer sequences
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
SI2332989T1 (sl) 2002-05-22 2015-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Imunoglobulinski bralni okvirji, ki kaĺ˝ejo izboljĺ ano stabilnost v intraceliäśnem okolju, in postopki za njihovo identifikacijo
EP1513879B1 (de) 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheken synthetischer antikörperphagen
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
GB0213745D0 (en) 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CA2824167C (en) * 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
ATE425183T1 (de) 2002-10-07 2009-03-15 Ludwig Inst For Cancer Res Ltd P53-bindendes polypeptid
AU2003285874A1 (en) * 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230201D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1587838B1 (de) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutische polypeptide, deren homologe, deren fragmente und deren verwendung bei der modulierung der thrombozytenvermittelten aggregation
EP1590369B1 (de) * 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Antagonisten von humanem il-1-beta
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20040248323A1 (en) 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
EP1498133A1 (de) 2003-07-18 2005-01-19 Aventis Pharma Deutschland GmbH Verwendung von pak-Inhibitoren zur Behandlung von Gelenkerkrankungen
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US20120202710A1 (en) * 2003-09-09 2012-08-09 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
CA2538284C (en) * 2003-09-15 2015-10-20 Rong-Hwa Lin Modulators of p-selectin glycoprotein ligand 1
EP2380985B1 (de) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Vitamin-K-Epoxid-Reduktase exprimierende Zellen und deren Verwendung
ATE466074T1 (de) 2003-10-14 2010-05-15 Baxter Int Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
JP4949038B2 (ja) 2003-12-01 2012-06-06 ダコ デンマーク アクティーゼルスカブ 免疫組織化学的検出のための方法および組成物
GB0328690D0 (en) 2003-12-10 2004-01-14 Ludwig Inst Cancer Res Tumour suppressor protein
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
GB0406215D0 (en) 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
HRP20110657T1 (hr) 2004-03-30 2011-10-31 Glaxo Group Limited Imunoglobulin koji se veže na osm
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
AU2005250055B2 (en) 2004-06-02 2008-09-11 Adalta Pty Ltd Binding moieties based on shark IgNAR domains
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
KR20070038556A (ko) 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20060134098A1 (en) * 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
GB0425739D0 (en) * 2004-11-23 2004-12-22 Procure Therapeutics Ltd Humanised baculovirus 2
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
CN101875957A (zh) 2004-12-30 2010-11-03 新加坡科技研究局 中国仓鼠凋亡相关基因
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
DK1836500T3 (da) 2005-01-14 2010-11-01 Ablynx Nv Fremgangsmåde og assays til at skelne mellem forskellige former af sygdomme og lidelser, der er kendetegnet ved thrombocytopeni og/eller ved spantan interaktion mellem von Willbrandfaktor 8vWF) og blodplader
JP4960951B2 (ja) 2005-03-11 2012-06-27 サノフイ Ｍｇｃ４５０４の使用
AU2005329450A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
JP2008539742A (ja) 2005-05-11 2008-11-20 サノフィ−アベンティス Ｇｉｐプロモーター多型の使用
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
PE20061444A1 (es) 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
CN103145839A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2500356A3 (de) 2005-08-19 2012-10-24 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3190125A1 (de) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Mittels engineering hergestellte anti-il-23r-antikörper
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
AU2006299438B9 (en) 2005-10-03 2013-07-18 Smith & Nephew, Inc. Locking instrument assembly
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
WO2007053524A2 (en) * 2005-10-28 2007-05-10 The Florida International University Board Of Trustees Horse: human chimeric antibodies
KR20080080109A (ko) 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
EP3299027A1 (de) 2005-11-04 2018-03-28 Genentech, Inc. Verwendung von komplementweginhibitoren zur behandlung von augenkrankheiten
EP1957531B1 (de) 2005-11-07 2016-04-13 Genentech, Inc. Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
AU2006338198B2 (en) 2005-12-02 2012-04-26 Genentech, Inc. Binding polypeptides and uses thereof
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
EP1954719A2 (de) 2005-12-02 2008-08-13 Genentech Inc. Zusammensetzungen und verfahren zur behandlung von krankheiten und leiden in zusammenhang mit zytokin-signalisierung sowie unter verwendung an il-22 und il-22r bindender antikörper
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
CN101400703B (zh) 2006-02-01 2013-05-08 赛法隆澳大利亚控股有限公司 结构域抗体构建体
WO2007100711A2 (en) 2006-02-24 2007-09-07 Investigen, Inc. Methods and compositions for detecting polynucleotides
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2007110219A1 (en) * 2006-03-27 2007-10-04 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
JP2009536527A (ja) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
MX2009001110A (es) * 2006-08-03 2009-05-11 Vaccinex Inc Anticuerpos monoclonales anti-il-6 y usos de los mismos.
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
US20100008910A1 (en) 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
KR101722261B1 (ko) 2006-10-02 2017-04-03 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
KR20140116546A (ko) 2006-10-27 2014-10-02 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
WO2008067547A2 (en) 2006-11-30 2008-06-05 Research Development Foundation Improved immunoglobulin libraries
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
KR20090088946A (ko) 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
JP5386364B2 (ja) 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
CN104524567A (zh) 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
US8664364B2 (en) 2007-01-24 2014-03-04 Carnegie Mellon University Optical biosensors
WO2008103702A2 (en) 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
EP2426145B1 (de) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Gentechnisch hergestellte anti-il-23p19-antikörper
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2447719B1 (de) 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteine
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
AU2008219684B2 (en) 2007-02-28 2014-04-17 Merck Sharp & Dohme Corp. Engineered anti-IL-23R antibodies
KR20140001229A (ko) 2007-03-30 2014-01-06 아보트 러보러터리즈 숙주 세포에서 재조합 단백질의 발현을 증강시키기 위한 재조합 발현 벡터 요소(ｒＥＶＥ)
US9969797B2 (en) * 2008-04-23 2018-05-15 Covalent Bioscience Incorporated Immunoglobulins directed to bacterial, viral and endogenous polypeptides
EP2139916A1 (de) 2007-04-26 2010-01-06 Opsona Therapeutics Limited Bindungsepitop des toll-like-rezeptors und zusammensetzungen zum daran binden
TWI570135B (zh) 2007-04-27 2017-02-11 建南德克公司 高效、穩定且非免疫抑制之抗－ｃｄ４抗體
AU2008247819B2 (en) 2007-05-01 2013-02-14 Research Development Foundation Immunoglobulin Fc libraries
CN101743253B (zh) 2007-05-17 2013-05-08 健泰科生物技术公司 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
PL2631248T3 (pl) 2007-06-15 2018-06-29 Medigene Ag Leczenie nowotworów z użyciem specyficznego przeciwciała anty-L1
ATE550648T1 (de) 2007-06-22 2012-04-15 Genera Istrazivanja D O O Adamts4 als blut-biomarker und therapeutisches ziel bei chronischem nierenversagen
EP2173772A2 (de) 2007-07-03 2010-04-14 Ablynx N.V. Bereitstellung verbesserter immunoglobulinsequenzen durch mutieren von cdr- und/oder fr-positionen
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2023144A1 (de) 2007-08-01 2009-02-11 Sanofi-Aventis Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes
US8734788B2 (en) 2007-08-03 2014-05-27 Opsona Therapeutics Ltd Composition and method for treatment of reperfusion injury and tissue damage
CN111909273B (zh) * 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
US8691730B2 (en) * 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2698390C (en) 2007-09-18 2018-05-22 Dako Denmark A/S A rapid and sensitive method for detection of biological targets
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
WO2009062102A2 (en) 2007-11-07 2009-05-14 Genentech, Inc. Compositions and methods for treatment of microbial disorders
AU2008326497B2 (en) 2007-11-19 2014-02-13 Genentech, Inc. Compositions and methods for inhibiting tumor progression
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
US9079947B2 (en) 2007-11-27 2015-07-14 The University Of British Columbia 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
EP2220120A2 (de) 2007-11-27 2010-08-25 Ablynx N.V. Gegen heterodimere cytokine und/oder deren rezeptoren gerichtete aminosäuresequenzen, und polypeptide, die diese enthalten
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
US8426153B2 (en) 2007-12-03 2013-04-23 Carnegie Mellon University Linked peptides fluorogenic biosensors
DK2851374T3 (en) 2007-12-14 2017-06-19 Bristol Myers Squibb Co Binding molecules to the human OX40 receptor
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
CN101965362A (zh) 2008-03-05 2011-02-02 埃博灵克斯股份有限公司 新型抗原结合二聚体-复合物及其制备方法和应用
US9873957B2 (en) * 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
EP2274333A4 (de) 2008-03-18 2011-06-15 Abbott Lab Verfahren zur behandlung von psoriasis
EP2105742A1 (de) 2008-03-26 2009-09-30 Sanofi-Aventis Verwendung von Kathepsin-C
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
EP2631302A3 (de) * 2008-03-31 2014-01-08 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Asthma
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
ES2528963T3 (es) * 2008-04-24 2015-02-13 Dyax Corp. Bibliotecas de paquetes genéticos que comprenden nuevos diseños de CDR1, CDR2, y CDR3 de HC y nuevos diseños de CDR1, CDR2, y CDR3 de LC
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
MX2010012142A (es) 2008-05-09 2011-04-05 Abbott Gmbh & Co Kg Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
WO2010006059A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP3629022A1 (de) 2008-07-25 2020-04-01 Richard W. Wagner Proteinscreeningverfahren
US8795981B2 (en) 2008-08-08 2014-08-05 Molecular Devices, Llc Cell detection
JP5756014B2 (ja) 2008-08-08 2015-07-29 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） がんの診断および治療のためのｖｈｚ
MY153074A (en) 2008-08-14 2014-12-31 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/11-23 antibodies
CN102143977B (zh) 2008-09-03 2014-08-06 霍夫曼-拉罗奇有限公司 多特异性抗体
JP5611210B2 (ja) 2008-09-07 2014-10-22 グリコネックス インコーポレイテッド 抗拡張ｉ型スフィンゴ糖脂質抗体、その誘導体および使用
EP2329261B1 (de) 2008-09-12 2014-06-18 Dako Denmark A/S Biomarker für prostatakrebs
US8417011B2 (en) 2008-09-18 2013-04-09 Molecular Devices (New Milton) Ltd. Colony detection
US20100081575A1 (en) * 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
US20100093563A1 (en) * 2008-09-22 2010-04-15 Robert Anthony Williamson Methods and vectors for display of molecules and displayed molecules and collections
WO2010034779A2 (en) 2008-09-24 2010-04-01 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Composition and method for treatment of preterm labor
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
EP2352764B1 (de) 2008-10-14 2018-03-28 Ablynx N.V. Aminosäuresequencen die an humanes cd4 und cxcr4, ccr5, tlr4, alphav integrin, beta3-integrin,beta1-integrin, humanes alpha2-integrin, cd81, sr-bi, claudin-1, claudin-6 bzw. claudin-9 binden und den viruseintritt neutralisieren.
EP2362767B1 (de) 2008-10-29 2017-12-06 Ablynx N.V. Formulierungen von einzeldomänen-antigen-bindungsmolekülen
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
EP2373689A1 (de) 2008-12-12 2011-10-12 MedImmune, LLC Kristalle und struktur einer humanen igg-fc-variante mit verst?rkter fcrn-bindung
EP3470425A3 (de) 2008-12-19 2019-07-17 Ablynx N.V. Verfahren zur erzeugung von immunoglobulinsequenzen
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
SG172855A1 (en) 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
EP2219029A1 (de) 2009-01-30 2010-08-18 Sanofi-Aventis Testsysteme, Verfahren und Verwendungen, die AS160-Protein einbeziehen
EP2398504B1 (de) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Verfahren und Kits zur Diagnose von Krebs und Vorhersage des therapeutischen Nutzens
CA2752385A1 (en) 2009-02-19 2010-08-26 Dako Denmark A/S Water soluble conjugate molecules comprising peroxidase substrate moieties
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US8420084B2 (en) 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
WO2011026948A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100437A2 (en) 2009-03-05 2010-09-10 University Of Sheffield Production of protein
EP2403531A4 (de) 2009-03-05 2013-02-27 Abbott Lab Il-17-bindende proteine
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
ES2551854T3 (es) 2009-04-30 2015-11-24 Ablynx N.V. Procedimiento para la producción de anticuerpos de dominio
CA2762837C (en) * 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
SG175407A1 (en) 2009-05-29 2011-11-28 Morphosys Ag A collection and methods for its use
ES2643034T3 (es) 2009-06-05 2017-11-21 Ablynx N.V. Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2766065C (en) * 2009-06-30 2020-07-21 Research Development Foundation Immunoglobulin fc polypeptides
JP2012531212A (ja) 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP2293072A1 (de) 2009-08-31 2011-03-09 Sanofi-Aventis Verwendung von Kathepsin H
EP2473852B1 (de) 2009-08-31 2016-03-30 Abbott Laboratories Biomarker zur vorhersage von schweren unerwünschten kardialen ereignissen und ihre verwendung
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
EP2473531A4 (de) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr-antikörper
KR20120112384A (ko) 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
US20110082054A1 (en) * 2009-09-14 2011-04-07 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20120282266A1 (en) 2009-10-16 2012-11-08 Auckland Uniservices Limited Anti-neoplastic uses of artemin antagonists
CA2777411C (en) 2009-10-20 2018-06-19 Dako Denmark A/S Immunochemical detection of single target entities
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
PH12012500843A1 (en) 2009-11-04 2019-07-10 Merck Sharp & Dohme Engineered anti-tslp antibody
EP2496944A2 (de) 2009-11-05 2012-09-12 Novartis AG Prädiktive biomarker für die progression von fibrose
WO2011058087A1 (en) 2009-11-11 2011-05-19 Gentian As Immunoassay for assessing related analytes of different origin
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CN102656190A (zh) 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
EP2513145B1 (de) 2009-12-14 2018-01-24 Ablynx N.V. Antikörper mit einzelner variabler domäne gegen ox40l, konstrukte und therapeutische verwendung
JP6214161B2 (ja) 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
RU2559542C2 (ru) 2009-12-23 2015-08-10 Дженентек, Инк. Антитела против bv8 и их применение
SG181814A1 (en) 2009-12-23 2012-07-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
MX339083B (es) 2010-01-28 2016-04-01 Glaxo Group Ltd Proteinas de enlace a cd127.
EP2354159A1 (de) 2010-02-05 2011-08-10 RWTH Aachen CCL17-Inhibitoren zur Verwendung bei von T-Helferzellen gesteuerten Erkrankungen
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
PT3501499T (pt) 2010-02-11 2022-11-22 Ablynx Nv Métodos e composições para a preparação de aerossóis
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
PE20130203A1 (es) 2010-03-17 2013-03-24 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
EP4234698A3 (de) 2010-05-06 2023-11-08 Novartis AG Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
KR101539684B1 (ko) 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
EP2577309B1 (de) 2010-05-25 2016-11-23 Carnegie Mellon University Gezielte sonden für zellphysiologie
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
WO2011161545A2 (en) 2010-06-04 2011-12-29 The Netherlands Cancer Institute Non-hydrolyzable protein conjugates, methods and compositions related thereto
WO2011158019A1 (en) 2010-06-16 2011-12-22 Adjuvantix Limited Polypeptide vaccine
BR112012027995A2 (pt) 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012006503A1 (en) 2010-07-09 2012-01-12 Genentech, Inc. Anti-neuropilin antibodies and methods of use
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
EP2596022A4 (de) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd Anti-il-23-heterodimer-spezifische antikörper
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013541501A (ja) 2010-08-03 2013-11-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
JP5841149B2 (ja) 2010-08-13 2016-01-13 ロシュ グリクアート アーゲー 抗テネイシンｃａ２抗体及び使用の方法
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
JP5813114B2 (ja) 2010-08-25 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｌ−１８ｒ１に対する抗体およびその使用
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130103734A (ko) 2010-08-31 2013-09-24 제넨테크, 인크. 바이오마커 및 치료 방법
CA3249351A1 (en) 2010-08-31 2025-07-03 Theraclone Sciences, Inc. Neutralizing antibodies against human immunodeficiency viruses (HIV)
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
WO2012038744A2 (en) 2010-09-22 2012-03-29 Genome Research Limited Detecting mutations
US8497138B2 (en) 2010-09-30 2013-07-30 Genetix Limited Method for cell selection
GB201016494D0 (en) 2010-09-30 2010-11-17 Queen Mary Innovation Ltd Polypeptide
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
DK2632946T3 (en) 2010-10-29 2018-03-12 Ablynx Nv PROCEDURE FOR MANUFACTURING VARIABLE IMMUNGLOBULIN SINGLE DOMAINS
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2816472A1 (en) 2010-11-08 2012-05-18 Dako Denmark A/S Quantification of single target molecules in histological samples
EA202092589A3 (ru) 2010-11-08 2021-06-30 Аблинкс Н.В. Cxcr2-связывающие полипептиды
MX346500B (es) 2010-11-10 2017-03-22 Genentech Inc * Metodos y composiciones para inmunoterapia para enfermedad neural.
RU2603080C2 (ru) 2010-11-19 2016-11-20 МорфоСис АГ Коллекция и способы ее применения
CA2817161C (en) 2010-12-06 2019-04-02 Dako Denmark A/S Combined histological stain
TWI732259B (zh) 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
TW201239097A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201241179A (en) 2010-12-17 2012-10-16 Sanofi Sa MiRNAs in joint disease
TW201238973A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201238974A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
PE20141114A1 (es) 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
CN103517921B (zh) 2010-12-21 2017-07-18 Abbvie 公司 IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
EP2655607A4 (de) 2010-12-21 2014-05-14 Univ North Carolina Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
WO2012085069A2 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Detection of a polypeptide dimer by a bivalent binding agent
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CA2817448C (en) 2010-12-23 2019-01-22 F. Hoffmann-La Roche Ag Binding agent
WO2012085064A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
EP2471554A1 (de) 2010-12-28 2012-07-04 Hexal AG Pharmazeutische Formulierung mit biopharmazeutischem Arzneimittel
US20140038842A1 (en) 2010-12-28 2014-02-06 Xoma Technology Cell surface display using pdz domains
AU2012214643B2 (en) 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides
MX2013009151A (es) 2011-02-10 2013-08-29 Roche Glycart Ag Inmunoterapia mejorada.
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
ES2688591T3 (es) 2011-03-28 2018-11-05 Ablynx N.V. Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
SG193552A1 (en) 2011-03-30 2013-11-29 Boehringer Ingelheim Int Anticoagulant antidotes
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
EP2511293A1 (de) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. Verfahren zur Steuerung der Hauptkomplex-N-Glycan-Strukturen und der sauren Varianten und Variabilität in Bioprozessen, die rekombinante Proteine produzieren
CA2832907C (en) 2011-04-19 2020-07-14 Dako Denmark A/S New method for enzyme-mediated signal amplification
US20120282176A1 (en) 2011-04-20 2012-11-08 Roche Glycart Ag Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier
EP2699597B1 (de) 2011-04-21 2016-06-01 Garvan Institute of Medical Research Modifizierte moleküle mit variablen domänen sowie herstellungs- und verwendungsverfahren dafür
EP2518157A1 (de) 2011-04-26 2012-10-31 Sanofi Testsysteme und Verfahren zur Identifizierung einer Verbindung, die die zelluläre DDR-Aktivität verändert
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CA2835094C (en) 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
LT3498732T (lt) 2011-05-06 2022-01-10 Zoetis Services Llc Anti-nervų augimo faktorių antikūnai ir jų paruošimo ir naudojimo būdai
ES2704007T3 (es) 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
GB2504887B (en) 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-Nerve growth factor antibodies and methods of preparing and using the same
EP3590950A1 (de) 2011-05-09 2020-01-08 Ablynx NV Verfahren zur herstellung von einzelvariablen immunglobulindomänen
KR101992502B1 (ko) 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
SI2710035T1 (sl) 2011-05-16 2017-07-31 F. Hoffmann-La Roche Ag Agonisti FGFR1 in tehnike njihove uporabe
EA032929B1 (ru) 2011-05-17 2019-08-30 Дзе Рокфеллер Юниверсити Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
US9580480B2 (en) 2011-05-31 2017-02-28 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
JP6187777B2 (ja) 2011-06-13 2017-08-30 シーエスエル、リミテッド Ｇ−ｃｓｆｒに対する抗体およびその使用
CA2837914A1 (en) 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
EP2537532A1 (de) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
IN2014CN00437A (de) 2011-06-23 2015-04-03 Ablynx Nv
DK2974737T3 (da) 2011-06-23 2026-01-19 Ablynx Nv Fremgangsmåder til forudsigelse, påvisning og reduktion af en specifik proteininterferens i assays, der involverer variable immunglobulin-enkeltdomæner
EP2944653A1 (de) 2011-06-23 2015-11-18 Ablynx N.V. Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
UA114478C2 (uk) 2011-06-28 2017-06-26 Берлін-Хемі Аг Антитіло, яке специфічно зв'язується з bst1
RS55716B1 (sr) 2011-06-28 2017-07-31 Oxford Biotherapeutics Ltd Terapeutski i dijagnostički cilj
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
EP2734236A4 (de) 2011-07-13 2015-04-15 Abbvie Inc Verfahren und zusammensetzungen zur behandlung von asthma mit anti-il-13-antikörpern
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
RU2014109038A (ru) 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX349095B (es) 2011-08-23 2017-07-11 Roche Glycart Ag Moleculas biespecificas de union a antigeno.
BR112014004168A2 (pt) 2011-08-23 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
EP2751139A1 (de) 2011-08-30 2014-07-09 NVIP Pty Ltd Caninisierte tumornekrosefaktor-antikörper und verfahren zu ihrer verwendung
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
ES2908046T3 (es) 2011-09-09 2022-04-27 Medimmune Ltd Anticuerpos anti-siglec-15 y usos de los mismos.
JP2014527180A (ja) 2011-09-14 2014-10-09 アベテルノ リミテッド 細胞内細胞選別
JP2014533927A (ja) 2011-09-15 2014-12-18 ジェネンテック， インコーポレイテッド 分化を促進する方法
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
GB201116116D0 (en) 2011-09-19 2011-11-02 Univ York Cell differentiation
ES2656442T3 (es) 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
SG11201400859SA (en) 2011-09-22 2014-04-28 Amgen Inc Cd27l antigen binding proteins
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
GB201116702D0 (en) 2011-09-28 2011-11-09 Procure Therapeutics Ltd Cell surface markers
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
CN103917556B (zh) 2011-10-14 2018-02-06 霍夫曼-拉罗奇有限公司 抗HtrA1抗体及使用方法
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
WO2013063114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
AU2012328917B2 (en) 2011-10-24 2017-05-25 Abbvie Inc. Bispecific immunobinders directed against TNF and IL-17
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
GB201118359D0 (en) 2011-10-25 2011-12-07 Univ Sheffield Pulmonary hypertension
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
PE20142312A1 (es) 2011-10-28 2015-01-25 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma
WO2013059886A1 (en) 2011-10-28 2013-05-02 Patrys Limited Pat-lm1 epitopes and methods for using same
GB201118840D0 (en) 2011-11-01 2011-12-14 Univ Sheffield Pulmonary hypertension II
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
AU2012335496B2 (en) 2011-11-11 2017-05-11 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
EP2782932A1 (de) 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Reinigung von anti-c-met-antikörpern
BR112014012882A2 (pt) 2011-11-29 2017-06-13 Genentech Inc método, anticorpo, polinucleotídeo, célula hospedeira, linhagem celular de hibridoma, uso do anticorpo e kit
CA2857597A1 (en) 2011-11-30 2013-06-06 AbbVie Deutschland GmbH & Co. KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
EP2794878B1 (de) 2011-12-22 2020-03-18 F.Hoffmann-La Roche Ag Expressionsvektororganisation, neuartige produktionszellenerzeugungsverfahren und ihre verwendung für die rekombinante erzeugung von polypeptiden
CN107119073A (zh) 2011-12-22 2017-09-01 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
EP3663314A1 (de) 2012-01-09 2020-06-10 The Scripps Research Institute Humanisierte antikörper mit ultralangem cdr3s
MX350378B (es) 2012-01-10 2017-09-05 Biogen Ma Inc Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
EP2804629A1 (de) 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5-antikörper und verwendungsverfahren
US20130183294A1 (en) 2012-01-18 2013-07-18 Genentech, Inc. Methods of using fgf19 modulators
NZ714482A (en) 2012-01-27 2017-08-25 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013113641A1 (en) 2012-01-31 2013-08-08 Roche Glycart Ag Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
CA2860600C (en) 2012-02-15 2022-07-26 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203587D0 (en) 2012-03-01 2012-04-11 Univ Warwick Modified bacterial cell
BR112014018374A8 (pt) 2012-03-02 2017-07-11 Roche Glycart Ag Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP2831587B1 (de) 2012-03-27 2018-05-16 Ventana Medical Systems, Inc. Signalisierungskonjugate und verwendungsverfahren dafür
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
AU2013256596A1 (en) 2012-05-01 2014-10-09 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
EP2666786A1 (de) 2012-05-21 2013-11-27 PAION Deutschland GmbH Immuntherapie für intrakraniale Blutungen
EP3605090A1 (de) 2012-05-23 2020-02-05 F. Hoffmann-La Roche AG Auswahlverfahren für therapeutika
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2855521A4 (de) 2012-05-24 2016-03-02 Mountgate Group Ltd Zusammensetzungen und verfahren in zusammenhang mit der vorbeugung und behandlung von tollwutinfektion
EP2861624A1 (de) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9-antikörper, formulierungen, dosierung und verfahren zur verwendung
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
JP6247287B2 (ja) 2012-07-04 2017-12-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ビオチン抗体および使用方法
EP3138578B1 (de) 2012-07-04 2022-01-12 F. Hoffmann-La Roche AG Anti-theophyllin-antikörper und verfahren zur verwendung davon
ES2604012T3 (es) 2012-07-04 2017-03-02 F. Hoffmann-La Roche Ag Conjugados de antígeno-anticuerpo unidos covalentemente
EP3578660A1 (de) 2012-07-05 2019-12-11 F. Hoffmann-La Roche AG Expressions- und sekretionssystem
EP2869851A1 (de) 2012-07-09 2015-05-13 Genentech, Inc. Immunkonjugate mit anti-cd22-antikörpern
US20140030280A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates
KR20150030698A (ko) 2012-07-09 2015-03-20 제넨테크, 인크. 항-cd79b 항체를 포함하는 면역접합체
IN2014DN10510A (de) 2012-07-09 2015-08-21 Genentech Inc
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AR092044A1 (es) 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
CA2876285A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
EP2882775B1 (de) 2012-08-09 2018-02-14 Roche Glycart AG Asgrp-antikörper und verwendungen davon
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
CA2887037A1 (en) 2012-10-02 2014-04-10 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activated matriptase
EP2904016B1 (de) 2012-10-08 2018-11-14 Roche Glycart AG Fc-freie antikörper mit zwei fab-fragmenten sowie verwendungsverfahren dafür
LT2908912T (lt) 2012-10-18 2020-09-25 The Rockefeller University Plačiai neutralizuojantys anti-živ antikūnai
WO2014063194A1 (en) 2012-10-23 2014-05-01 The University Of Sydney Elastic hydrogel
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
SG10201700488QA (en) 2012-11-13 2017-02-27 Genentech Inc Anti-hemagglutinin antibodies and methods of use
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
BR112015013627A2 (pt) 2012-12-10 2017-07-11 Elastagen Pty Ltd elástico escalável tridimensional, fabricação e construção
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
EP2938637A2 (de) 2012-12-28 2015-11-04 AbbVie Inc. Proteinzusammensetzungen mit multivalenter bindung
EP2945652B1 (de) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Verfahren zur behandlung cholangiokarzinom
WO2014116596A1 (en) 2013-01-22 2014-07-31 Abbvie, Inc. Methods for optimizing domain stability of binding proteins
EP2948475A2 (de) 2013-01-23 2015-12-02 AbbVie Inc. Verfahren und zusammensetzungen zur modulierung einer immunantwort
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2948478B1 (de) 2013-01-25 2019-04-03 Amgen Inc. Antikörper gegen cdh19 für melanome
US9840559B2 (en) 2013-02-01 2017-12-12 The Regents Of The University Of California Anti-CD83 antibodies and use thereof
CN104995211B (zh) 2013-02-07 2019-09-13 Csl有限公司 Il-11r结合蛋白及其应用
US20140228875A1 (en) 2013-02-08 2014-08-14 Nidus Medical, Llc Surgical device with integrated visualization and cauterization
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2958592A1 (de) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Verfahren zur behandlung von krebs und zur verhinderung von arzneimittelresistenz
CN105143270B (zh) 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
CA2896359A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
RU2015140921A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Антитела к mcsp
MX375359B (es) 2013-02-26 2025-03-06 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de células t.
CA2902068C (en) 2013-02-28 2023-10-03 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
ES2843786T3 (es) 2013-03-13 2021-07-20 Seagen Inc Filtración con carbono activado para la purificación de ADC de benzodiazepina
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
PL2968467T3 (pl) 2013-03-13 2020-10-19 F. Hoffmann-La Roche Ag Preparaty o zmniejszonym utlenianiu
IL269947B (en) 2013-03-13 2022-08-01 Genentech Inc Formulations with reduced oxidation
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2970479B1 (de) 2013-03-14 2019-04-24 Novartis AG Antikörper gegen notch 3
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CN113549148B (zh) 2013-03-14 2025-11-21 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
KR20150127216A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 암의 치료 및 암 약물 내성의 예방 방법
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP2016515132A (ja) 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
EP2970471A2 (de) 2013-03-15 2016-01-20 F. Hoffmann-La Roche AG Anti-crth2-antikörper und deren verwendung
SG10201706210WA (en) 2013-03-15 2017-09-28 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers
SI2970875T2 (sl) 2013-03-15 2026-03-31 F. Hoffmann-La Roche Ag Sestavki celičnih kultur z antioksidanti in postopki za proizvodnjo polipeptidov
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
CN105209076A (zh) 2013-03-15 2015-12-30 阿布维公司 抗体药物偶联物(adc)纯化
CN105143258B (zh) 2013-03-15 2020-06-23 Ac免疫有限公司 抗Tau抗体和使用方法
EP2968544A4 (de) 2013-03-15 2016-10-12 Hoffmann La Roche Zellkulturmedien und verfahren zur antikörperherstellung
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
KR20220041957A (ko) 2013-03-15 2022-04-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
GB201306589D0 (en) 2013-04-11 2013-05-29 Abeterno Ltd Live cell imaging
US20160145325A1 (en) 2013-04-29 2016-05-26 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
WO2014189973A2 (en) 2013-05-20 2014-11-27 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
SI3456743T1 (sl) 2013-05-30 2022-01-31 Kiniksa Pharmaceuticals, Ltd. Proteini, ki vežejo antigen receptorja onkostatina M
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
KR102062784B1 (ko) 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
PE20160671A1 (es) 2013-08-02 2016-07-09 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
JP6382311B2 (ja) 2013-08-13 2018-08-29 エラスタジェン・プロプライエタリー・リミテッドＥｌａｓｔａｇｅｎ Ｐｔｙ Ｌｔｄ 損傷組織の再生
WO2015042108A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
MX375378B (es) 2013-09-27 2025-03-06 Genentech Inc Formulaciones de anticuerpos anti-pdl1.
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3733244A1 (de) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralisierende antiinflueanza-a-virus-antikörper und verwendungen davon
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
KR20160068855A (ko) 2013-10-11 2016-06-15 제넨테크, 인크. Nsp4 억제제 및 사용 방법
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
CN105744954B (zh) 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
SG11201603127WA (en) 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
US10203327B2 (en) 2013-11-05 2019-02-12 Novartis Ag Organic compounds
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2924268C (en) 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
HRP20250551T1 (hr) 2013-11-27 2025-06-20 Zymeworks Bc Inc. Bispecifični antigen-vezujući konstrukti koji ciljaju her2
JP6612246B2 (ja) 2013-11-28 2019-11-27 シーエスエル、リミテッド 腎症を処置する方法
WO2015084883A2 (en) 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
US9309314B2 (en) 2013-12-03 2016-04-12 Agency For Science, Technology And Research (A*Star) Polypeptides, nucleic acids and uses thereof
KR102311761B1 (ko) 2013-12-09 2021-10-13 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
EA201691214A1 (ru) 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
MX2016007885A (es) 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
UA129760C2 (uk) 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
US10543270B2 (en) 2013-12-18 2020-01-28 Csl Limited Methods of treating wounds in a diabetic subject
HRP20200384T1 (hr) 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
CA2933384A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
CA2932547C (en) 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
US20170043034A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
SG11201606490YA (en) 2014-02-08 2016-09-29 Genentech Inc Methods of treating alzheimer's disease
RU2724190C2 (ru) 2014-02-08 2020-06-23 Дженентек, Инк. Способы лечения болезни альцгеймера
PL3105253T3 (pl) 2014-02-12 2018-12-31 F. Hoffmann-La Roche Ag Przeciwciała anty-Jagged1 i sposoby stosowania
RU2019119862A (ru) 2014-02-20 2019-07-15 Аллерган, Инк. Антитела к компоненту комплемента c5
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
AU2015223056B2 (en) 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
CA2939931C (en) 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
EP3116999B1 (de) 2014-03-14 2021-09-15 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen für die sekretion von heterologen polypeptiden
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
EP3119490B1 (de) 2014-03-21 2021-09-08 F. Hoffmann-La Roche AG In-vitro-prognose von in-vivo-halbwertzeit von antikörpern
EP3122900A1 (de) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Krebsbehandlung mit c-met-antagonisten und korrelation desselben mit hgf-expression
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
EP3126394B1 (de) 2014-03-31 2019-10-30 F.Hoffmann-La Roche Ag Anti-ox40-antikörper und verfahren zur verwendung
MX388380B (es) 2014-04-18 2025-03-19 Acceleron Pharma Inc Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
DK3140653T3 (da) 2014-05-08 2022-06-20 Novodiax Inc Direkte immunhistokemianalyse
EP3142700B1 (de) 2014-05-16 2021-03-03 Medimmune, LLC Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
WO2015179658A2 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191596A1 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
WO2015191610A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
WO2015191590A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US10758613B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
WO2015191615A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
BR112016028838A2 (pt) 2014-06-11 2017-10-24 Genentech Inc anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
KR20170026362A (ko) 2014-06-26 2017-03-08 에프. 호프만-라 로슈 아게 항-ｂｒｄｕ 항체 및 사용 방법
WO2016004370A1 (en) 2014-07-03 2016-01-07 Genentech, Inc. Polypeptide expression systems
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EP3166976B2 (de) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1-kombinationen zur tumorbehandlung
ES2916923T3 (es) 2014-07-11 2022-07-06 Ventana Med Syst Inc Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
ES2799404T3 (es) 2014-07-15 2020-12-17 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Polipéptidos de CD44 aislados y usos de los mismos
JP6464255B2 (ja) 2014-08-04 2019-02-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｔ細胞活性化抗原結合分子
WO2016033331A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR20170066421A (ko) 2014-09-12 2017-06-14 제넨테크, 인크. 항-cll-1 항체 및 면역접합체
LT3191135T (lt) 2014-09-12 2020-11-25 Genentech, Inc. Anti-her2 antikūnai ir imunokonjugatai
JP6943760B2 (ja) 2014-09-12 2021-10-06 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及び免疫複合体
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
HK1243629A1 (zh) 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
PL3204095T3 (pl) 2014-10-10 2019-10-31 Ablynx Nv Urządzenie do inhalacji do stosowania w terapii aerozolowej chorób układu oddechowego
RU2017115670A (ru) 2014-10-10 2018-11-15 Аблинкс Н.В. Лечение инфекции рсв
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
WO2016061617A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
US10584175B2 (en) 2014-10-23 2020-03-10 La Trobe University FN14-binding proteins and uses thereof
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
CA2963720C (en) 2014-10-29 2024-05-14 Seattle Genetics, Inc. Dosage and administration of non-fucosylated anti-cd40 antibodies
MX2017005751A (es) 2014-11-03 2018-04-10 Genentech Inc Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
EP3215850B1 (de) 2014-11-03 2019-07-03 F. Hoffmann-La Roche AG Tests zum nachweis von te-zell-immununtergruppen und verfahren zur verwendung davon
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria
MX382952B (es) 2014-11-05 2025-03-13 Genentech Inc Métodos de producción de proteínas de cadena doble en bacterias.
CA2966548A1 (en) 2014-11-05 2016-05-12 Agrosavfe Nv Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
EP3217787B1 (de) 2014-11-10 2019-04-17 F.Hoffmann-La Roche Ag Tiermodell für nephropathie und mittel zur behandlung davon
CR20170194A (es) 2014-11-14 2017-07-10 Hoffmann La Roche Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
CN107429075B (zh) 2014-11-17 2022-11-01 卡内基梅隆大学 可激活的双组份光敏剂
EP3221362B1 (de) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3221361B1 (de) 2014-11-19 2021-04-21 Genentech, Inc. Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
MA40938A (fr) 2014-12-05 2017-10-11 Hoffmann La Roche Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
RU2017120039A (ru) 2014-12-10 2019-01-10 Дженентек, Инк. Антитела к рецепторам гематоэнцефалического барьера и способы их применения
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN114478773A (zh) 2015-01-09 2022-05-13 阿达尔塔有限公司 Cxcr4结合分子
CN107428823B (zh) 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
WO2016118947A1 (en) 2015-01-23 2016-07-28 The University Of North Carolina At Chapel Hill Apparatuses, systems, and methods for preclinical ultrasound imaging of subjects
EP3253791A1 (de) 2015-02-03 2017-12-13 INSERM - Institut National de la Santé et de la Recherche Médicale Konformationelle anti-rho-gtpase-einzeldomänenantikörper und verwendungen davon
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6724023B2 (ja) 2015-02-09 2020-07-15 リサーチ ディベロップメント ファウンデーション 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3271723A1 (de) 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Verfahren für den nachweis und die quantifizierung von il-13 und verwendungen in der diagnostik und behandlung von th2-assoziierten erkrankungen
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
US10227392B2 (en) 2015-04-06 2019-03-12 Acceleron Pharma Inc. ALK7:ActRIIB heteromultimers and uses thereof
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
AU2016246695A1 (en) 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
CN113552350B (zh) 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
EP3286315B1 (de) 2015-04-24 2021-05-26 F. Hoffmann-La Roche AG Verfahren zur identifizierung von bakterien mit bindenden polypeptiden
EP3288584A2 (de) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
EP3778640A1 (de) 2015-05-01 2021-02-17 Genentech, Inc. Maskierte anti-cd3-antikörper und verfahren zur verwendung
WO2016183104A1 (en) 2015-05-11 2016-11-17 Genentech, Inc. Compositions and methods of treating lupus nephritis
RS61152B2 (sr) 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
EP3095465A1 (de) 2015-05-19 2016-11-23 U3 Pharma GmbH Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
WO2016196343A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use
JP7144935B2 (ja) 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
US10174121B2 (en) 2015-05-29 2019-01-08 Abbvie, Inc. Anti-CD40 antibodies
EP3302467A4 (de) 2015-05-31 2019-01-02 Curegenix Corporation Kombinationszusammensetzungen zur immuntherapie
EP3302552A1 (de) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Zusammensetzungen und verfahren zur verwendung von anti-il-34-antikörpern zur behandlung von neurologischen erkrankungen
EP4465050A3 (de) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau-antikörper und verfahren zur verwendung
KR20180011839A (ko) 2015-06-08 2018-02-02 제넨테크, 인크. 항-ox40 항체를 이용한 암의 치료 방법
HK1251474A1 (zh) 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
TWI731861B (zh) 2015-06-16 2021-07-01 美商建南德克公司 FcRH5之人源化及親和力成熟抗體及使用方法
EP3916018A1 (de) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3-antikörper und verfahren zur verwendung
EP3310378B1 (de) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1-antikörper und verfahren zur verwendung
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
CN107787331B (zh) 2015-06-17 2022-01-11 豪夫迈·罗氏有限公司 抗her2抗体和使用方法
JP6896650B2 (ja) 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
WO2016207091A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
US9861621B2 (en) 2015-06-29 2018-01-09 Biomed Valley Discoveries, Inc. LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
KR20180021864A (ko) 2015-06-29 2018-03-05 제넨테크, 인크. 장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
CA3162816A1 (en) 2015-06-29 2017-01-05 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
PT3316909T (pt) 2015-06-30 2023-11-22 Seattle Genetics Inc Anticorpos anti-ntb-a e composições e métodos relacionados
WO2017023866A1 (en) 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3341415B1 (de) 2015-08-28 2021-03-24 H. Hoffnabb-La Roche Ag Anti-hypusin-antikörper und verwendungen davon
KR20230079500A (ko) 2015-09-18 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
US11078251B2 (en) 2015-09-18 2021-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
JP6904947B2 (ja) 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
AU2016326738B2 (en) 2015-09-24 2023-08-31 Abvitro Llc HIV antibody compositions and methods of use
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
WO2017055484A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of lymphomas
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
CA2996902C (en) 2015-10-02 2020-06-02 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
US20170096485A1 (en) 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
CR20180151A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Antcuierpos anti-pd1 y métodos de uso
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
EP3356407B1 (de) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispezifische anti-cd19xcd3-t-zell-aktivierende antigenbindende moleküle
WO2017055388A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
NZ739090A (en) 2015-10-02 2025-06-27 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
EP3356410B1 (de) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispezifische anti-ceaxcd3-t-zell-aktivierende antigenbindende moleküle
WO2017060144A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor
EP3362088B1 (de) 2015-10-12 2020-11-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Zur verringerung von cd8-t-zellen fähiger wirkstoff zur behandlung von myokardinfarkt oder akutem myokardinfarkt
EP3362100B1 (de) 2015-10-16 2022-06-22 Genentech, Inc. Gehinderte disulfidwirkstoffkonjugate
EP3365025B1 (de) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antikörper-arzneimittelkonjugate und verfahren zur verwendung
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
AU2016344665C1 (en) 2015-10-29 2023-07-27 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
KR102162324B1 (ko) 2015-10-30 2020-10-07 제넨테크, 인크. 항-HtrA1 항체 및 이의 사용 방법
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3371217B1 (de) 2015-11-08 2025-06-11 F. Hoffmann-La Roche AG Screening verfahren für multispezifische antikörper
WO2017081190A1 (en) 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
ES2911027T3 (es) 2015-11-20 2022-05-17 AusVir Therapeutics Pty Ltd Compuestos para aplicaciones medicinales
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
WO2017089618A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US10894834B2 (en) 2015-11-27 2021-01-19 Csl Limited CD131 binding proteins
EP4026848A1 (de) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur reduktion des zytokin-freisetzungssyndroms
EP3178848A1 (de) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
US11135304B2 (en) 2015-12-18 2021-10-05 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
IL259256B2 (en) 2015-12-18 2023-02-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
TWI605057B (zh) 2015-12-18 2017-11-11 中外製藥股份有限公司 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
EP3397243A1 (de) 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Verwendung von tryptophanderivaten für proteinformulierungen
WO2017118634A1 (en) 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
CN107531795B (zh) 2016-01-05 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
JP6949030B2 (ja) 2016-01-08 2021-10-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
BR112018014762A2 (pt) 2016-01-20 2018-12-26 Genentech Inc método de tratamento da doença de alzheimer (da) precoce
WO2017129558A1 (en) 2016-01-25 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
JP6902040B2 (ja) 2016-01-28 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫チェックポイント阻害剤の効力を増強する方法
WO2017129790A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancer
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
EP3423105B1 (de) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Antikörper-wirkstoff-konjugate auf eribulinbasis und verfahren zur verwendung
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
CN116196412A (zh) 2016-03-15 2023-06-02 中外制药株式会社 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
CR20180453A (es) 2016-03-22 2018-12-05 Hoffmann La Roche Moleculas biespecíficas de células t activadas por proteasas
HRP20230528T1 (hr) 2016-03-22 2023-08-04 F. Hoffmann - La Roche Ag Bispecifične molekule t stanica aktivirane proteazom
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3231813A1 (de) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
AU2017241776B2 (en) 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
US20200330459A1 (en) 2016-04-06 2020-10-22 Inserm (Institut National De La Santé Et La Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
EP3443004A1 (de) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3-antikörper und verfahren zur verwendung
PL3443012T3 (pl) 2016-04-15 2026-04-20 Bioatla, Inc. Przeciwciała anty-axl, fragmenty przeciwciał i ich immunokoniugaty oraz ich zastosowania
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
CN109154613A (zh) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 用于监测和治疗癌症的方法
US20190125826A1 (en) 2016-04-22 2019-05-02 Inserm (Institut National De La Santé Et De La Médicale) Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
AU2017259869A1 (en) 2016-05-02 2018-09-27 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
CN109310788A (zh) 2016-05-03 2019-02-05 法国国家健康和医学研究院 Cd31shed作为分子靶标用于炎症成像
EP3452092B1 (de) 2016-05-06 2020-08-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmazeutische zusammensetzungen zur behandlung von chemoresistenter akuter myeloischer leukämie (aml)
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
EP3243836A1 (de) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3455254B1 (de) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und einem tenascin-bindungsteil
CN116751298A (zh) * 2016-05-13 2023-09-15 生物蛋白有限公司 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
EP3243832A1 (de) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
AU2017266298B2 (en) 2016-05-18 2024-01-04 Boehringer Ingelheim International Gmbh Anti PD-1 and anti-LAG3 antibodies for cancer treatment
EP3458101B1 (de) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac-antikörper-konjugate und verfahren zur verwendung
EP3463452A1 (de) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von nicht-kleinzelligem lungenkrebs (nsclc), der mit chronisch obstruktiver lungenerkrankung (copd) koexistiert
EP3465221B1 (de) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
WO2017202890A1 (en) 2016-05-27 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating myeloma
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
EP3252078A1 (de) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
BR112018075639A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. conjugados de anticorpo fármaco anti-egfr
EP3458479B1 (de) 2016-06-08 2020-11-04 AbbVie Inc. Anti-b7-h3-antikörper und antikörper-wirkstoff-konjugate
BR112018075644A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-cd98 e conjugados de anticorpo e fármaco
CN116173232A (zh) 2016-06-08 2023-05-30 艾伯维公司 抗cd98抗体及抗体药物偶联物
EP3469000A1 (de) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3-antikörper und antikörperarzneimittelkonjugate
BR112018075630A2 (pt) 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
JP2019521975A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
CN109563168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
UA126799C2 (uk) 2016-06-10 2023-02-08 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'югований імуноглобулін
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR102306744B1 (ko) 2016-06-17 2021-09-28 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
EP3475298A1 (de) 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Multispezifische anti-polyubiquitin-antikörper
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
HRP20210694T1 (hr) 2016-07-15 2021-09-17 Acceleron Pharma, Inc. Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
PL3490582T3 (pl) 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
BR112019001693A2 (pt) 2016-07-29 2019-07-02 INSERM (Institut National de la Santé et de la Recherche Médicale) anticorpos direcionados a macrófagos associados a tumores e seus usos
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP4282877A3 (de) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Gegen bcma gerichtete chimäre antigenrezeptoren und verfahren zur verwendung davon
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3510407A1 (de) 2016-09-08 2019-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur diagnose und behandlung des nephrotischen syndroms
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
KR102557643B1 (ko) 2016-09-23 2023-07-20 제넨테크, 인크. 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
WO2018053597A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
EP3519049B1 (de) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Sicheres und effizientes verfahren zur behandlung von psoriasis mit anti-il23-spezifischem antikörper
ES2897217T3 (es) 2016-09-30 2022-02-28 Hoffmann La Roche Anticuerpos biespecíficos frente a p95HER2
BR112019006993A2 (pt) 2016-10-05 2019-09-03 Acceleron Pharma Inc heteromultímeros de alk4:actriib e usos dos mesmos
EP3522933B1 (de) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Verfahren zur herstellung von antikörperarzneimittelkonjugaten
JP2019529509A (ja) 2016-10-05 2019-10-17 アクセレロン ファーマ インコーポレーテッド 腎臓疾患を治療するための組成物および方法
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
US11149082B2 (en) 2016-10-17 2021-10-19 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
EP3532091A2 (de) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic-antikörper und verfahren zur verwendung
WO2018087391A1 (en) 2016-11-14 2018-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CA3043515A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
MX2019005661A (es) 2016-11-16 2019-10-07 Janssen Biotech Inc Método para tratar la psoriasis con el anticuerpo específico anti-il23.
US20210277145A1 (en) 2016-11-17 2021-09-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for increasing endogenous protein level
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
TWI797097B (zh) 2016-11-28 2023-04-01 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
EP3548894B1 (de) 2016-12-02 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur diagnose eines nierenzellkarzinoms
MA48595A (fr) 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
EP3555620A1 (de) 2016-12-13 2019-10-23 H. Hoffnabb-La Roche Ag Verfahren zur bestimmung des vorhandenseins eines zielantigens in einer tumorprobe
RU2019121662A (ru) 2016-12-16 2021-01-18 Мерк Патент Гмбх Способы использования галектин-3-связывающего белка, обнаруживаемого в моче, для мониторинга тяжести и прогрессирования волчаночного нефрита
EP3554544A4 (de) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. Anti-cub-haltige protein 1-(cdcp1)-antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
WO2018114754A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
AU2017384126B2 (en) 2016-12-20 2025-01-23 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3360898A1 (de) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
CN108261544B (zh) 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261391B (zh) 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
BR112019013189A2 (pt) 2017-01-03 2019-12-10 Hoffmann La Roche moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa
WO2018134389A1 (en) 2017-01-23 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating infections
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US20190367611A1 (en) 2017-02-01 2019-12-05 CentryMed Pharmaceutical Inc. Monomeric human igg1 fc and bispecific antibodies
MA47442A (fr) 2017-02-07 2019-12-18 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
PE20191548A1 (es) 2017-02-10 2019-10-24 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
CA3054623A1 (en) 2017-02-28 2018-09-07 Vib Vzw Means and methods for oral protein delivery
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
SG10202107829YA (en) 2017-03-22 2021-08-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CA3056248A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
US20210186982A1 (en) 2017-03-24 2021-06-24 Universite Nice Sophia Antipolis Methods and compositions for treating melanoma
TW201900672A (zh) 2017-03-27 2019-01-01 瑞士商赫孚孟拉羅股份公司 改良之抗原結合受體型式
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
WO2018178029A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
WO2018178030A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
EP3601325B1 (de) 2017-03-28 2023-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Neue arten von tau
KR20190133162A (ko) 2017-03-28 2019-12-02 제넨테크, 인크. 신경퇴행성 질병의 치료 방법
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
EP3601345A1 (de) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
EP3601346A1 (de) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
WO2018178936A1 (en) 2017-03-30 2018-10-04 Duke University Radiolabeled biomolecules and their use
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
AU2018247796A1 (en) 2017-04-04 2019-08-29 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
SI3606954T1 (sl) 2017-04-05 2022-10-28 F. Hoffmann - La Roche Ag Protitelesa proti LAG3
TWI690538B (zh) 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
EP3612648A1 (de) 2017-04-18 2020-02-26 Université Libre de Bruxelles Biomarker und targets für proliferative erkrankungen
US12460208B2 (en) 2017-04-18 2025-11-04 Parr Biotechnology Co., Ltd. Immunomodulatory polynucleotides and uses thereof
CN108728444A (zh) 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 免疫调节性多核苷酸及其应用
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
SG11201909048TA (en) 2017-04-21 2019-11-28 Genentech Inc Use of klk5 antagonists for treatment of a disease
EP3615572A1 (de) 2017-04-27 2020-03-04 Tesaro Inc. Gegen lymphozytenaktivierungsgen 3 (lag-3) gerichtete antikörpermittel und verwendungen davon
KR20200016232A (ko) 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
EP3625251A1 (de) 2017-05-15 2020-03-25 University Of Rochester Breit neutralisierende monoklonale anti-influenza-antikörper und verwendungen davon
EP3403649A1 (de) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitoren und antagonisten von gpr84 zur behandlung von endometriose
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
EP3406253A1 (de) 2017-05-24 2018-11-28 Bayer Aktiengesellschaft Inhibitoren und antagonisten von humanem pycr1
EP3630182A4 (de) * 2017-05-24 2021-02-24 Development Center for Biotechnology Humanisierte antikörper gegen globo h und ihre verwendung in der krebsbehandlung
EP3409322A1 (de) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Behandlungsverfahren
IL270908B1 (en) 2017-06-02 2026-04-01 Merck Patent Gmbh ADAMTS-binding immunoglobulins
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
EP3630818A1 (de) 2017-06-02 2020-04-08 Ablynx NV Aggrecanbindende immunglobuline
TW202428621A (zh) 2017-06-02 2024-07-16 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
WO2018224615A1 (en) 2017-06-08 2018-12-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating hyperpigmentation disorders
ES2986584T3 (es) 2017-06-08 2024-11-12 Institut Nat De La Sante Et De Larecherche Medicale Inserm Receptor quimérico para su uso en sensores de células completas para detectar analitos de interés
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
JP7264831B2 (ja) * 2017-06-15 2023-04-25 ディベロップメント センター フォー バイオテクノロジー 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用
US20210403573A1 (en) 2017-06-22 2021-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019002548A1 (en) 2017-06-29 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
KR102625929B1 (ko) 2017-07-19 2024-01-16 브이아이비 브이지더블유 혈청 알부민 결합제
WO2019016310A1 (en) 2017-07-20 2019-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND COMPOSITIONS FOR TREATING CANCERS
KR102922386B1 (ko) 2017-07-21 2026-02-04 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
CN110869050B (zh) 2017-07-28 2024-07-02 豪夫迈·罗氏有限公司 双特异性抗体配制剂
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
US20200197547A1 (en) 2017-08-30 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers
CN111670198B (zh) 2017-09-11 2023-12-15 莫纳什大学 人凝血酶受体par4的结合蛋白
EP3457139A1 (de) 2017-09-19 2019-03-20 Promise Advanced Proteomics Antikörperähnliche peptide zur quantifizierung therapeutischer antikörper
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
WO2019057742A1 (en) 2017-09-20 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF AUTOPHAGIA
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
KR20200067197A (ko) 2017-10-20 2020-06-11 에프. 호프만-라 로슈 아게 단일특이적 항체로부터 다중특이적 항체의 생성 방법
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
BR112020007736A2 (pt) 2017-10-30 2020-10-20 F. Hoffmann-La Roche Ag composição e método de tratamento
CA3076791A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019086499A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Novel tnf family ligand trimer-containing antigen binding molecules
JP2021500930A (ja) 2017-11-01 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｐボディ−多価標的結合物質
BR112020006443A2 (pt) 2017-11-01 2020-09-29 F. Hoffmann-La Roche Ag anticorpos biespecíficos, ácido nucleico isolado, vetor ou célula hospedeira, método para produzir um anticorpo biespecífico e para tratar um indivíduo, composição farmacêutica e uso do anticorpo
KR20200084006A (ko) 2017-11-01 2020-07-09 에프. 호프만-라 로슈 아게 표적화된 ox40 작용제를 사용하는 병용 요법
ES2984919T3 (es) 2017-11-06 2024-10-31 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
IL274272B2 (en) 2017-11-06 2025-09-01 Janssen Biotech Inc A safe and effective method for treating psoriatic arthritis with a specific anti-IL23 antibody
EP3706795A4 (de) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. Verfahren und zusammensetzungen zur erzeugung und verwendung von humanisierten konformationsspezifischen phosphorylierten tau-antikörpern
EP3710589A4 (de) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-c1s-antikörper und verfahren zur verwendung
US11787874B2 (en) 2017-11-15 2023-10-17 Novo Nordisk A/S Factor X binders enhancing FX activation
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019101995A1 (en) 2017-11-27 2019-05-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for cardiac regeneration
CN111836828B (zh) 2017-11-28 2024-12-20 中外制药株式会社 包括抗原结合结构域和运送部分的多肽
CA3081770A1 (en) 2017-11-29 2019-06-06 Csl Limited Method of treating or preventing ischemia-reperfusion injury
MA50943A (fr) 2017-12-01 2020-10-07 Seattle Genetics Inc Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
CA3079039A1 (en) 2017-12-14 2019-06-20 F. Hoffmann-La Roche Ag Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer
JP7774283B2 (ja) 2017-12-19 2025-11-21 ザ ロックフェラー ユニバーシティー エフェクター機能を改良したヒトＩｇＧのＦｃ領域改変体
WO2019122046A1 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Universal reporter cell assay for specificity test of novel antigen binding moieties
JP2021508246A (ja) 2017-12-21 2021-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ
EP3502140A1 (de) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
SG11202005632SA (en) 2017-12-21 2020-07-29 Hoffmann La Roche Antibodies binding to hla-a2/wt1
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
JP7490565B2 (ja) 2017-12-29 2024-05-27 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
EP3735590A1 (de) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur behandlung von resistentem melanom
EP3737692A4 (de) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Calreticulin-bindende konstrukte und gentechnisch veränderte t-zellen zur behandlung von krankheiten
EP3740507A4 (de) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. Einzeldomänenantikörper und varianten davon gegen pd-1
EP3740505A1 (de) 2018-01-16 2020-11-25 Lakepharma Inc. Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
JP2021510594A (ja) 2018-01-25 2021-04-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 臓器の虚血再灌流傷害を予防する方法における使用のためのｉｌ−３３のアンタゴニスト
CN111630063A (zh) 2018-01-31 2020-09-04 豪夫迈·罗氏有限公司 稳定化的免疫球蛋白结构域
US20200354457A1 (en) 2018-01-31 2020-11-12 Hoffmann-La Roche Inc. Bispecific antibodies comprising an antigen-binding site binding to lag3
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019154867A1 (en) 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
JP7475275B2 (ja) 2018-02-08 2024-04-26 ジェネンテック， インコーポレイテッド 二重特異性抗原結合分子及びその使用方法
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
EP3749682B1 (de) 2018-02-09 2025-09-24 Acceleron Pharma Inc. Treating heterotopic ossification
WO2019158675A1 (en) 2018-02-16 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating vitiligo
CN111836831A (zh) 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
EP3758742A1 (de) 2018-03-01 2021-01-06 Vrije Universiteit Brussel Menschliche pd-l1-bindende immunglobuline
WO2019166453A1 (en) 2018-03-01 2019-09-06 F. Hoffmann-La Roche Ag Specificity assay for novel target antigen binding moieties
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
IL277174B2 (en) 2018-03-13 2025-12-01 Hoffmann La Roche Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US11485782B2 (en) 2018-03-14 2022-11-01 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765031A4 (de) 2018-03-14 2022-03-23 Memorial Sloan Kettering Cancer Center Anti-polysialsäure-antikörper und verwendungen davon
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US12202894B2 (en) 2018-03-20 2025-01-21 WuXi Biologics Ireland Limited Anti-TIM-3 antibodies
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
EP3768701B1 (de) 2018-03-23 2023-08-02 Université Libre de Bruxelles Agonistenmoleküle des wnt-signalwegs
HRP20260157T1 (hr) 2018-03-29 2026-03-27 F. Hoffmann - La Roche Ag Moduliranje laktogene aktivnosti u stanicama sisavaca
AU2019241350B2 (en) 2018-03-30 2025-10-02 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
JP7104458B2 (ja) 2018-04-02 2022-07-21 上海博威生物医薬有限公司 リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
EP3775902B1 (de) 2018-04-04 2023-02-22 F. Hoffmann-La Roche AG Diagnostische assays zum nachweis von tumorantigenen bei krebspatienten
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
WO2019192972A1 (en) 2018-04-04 2019-10-10 F. Hoffmann-La Roche Ag Diagnostic assays to detect tumor antigens in cancer patients
EP3552631A1 (de) 2018-04-10 2019-10-16 Inatherys Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
CR20200459A (es) 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
EP3787678A1 (de) 2018-05-03 2021-03-10 University Of Rochester Monoklonale neuraminidase-antikörper gegen influenza und ihre verwendungen
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
JP7206297B2 (ja) 2018-05-18 2023-01-17 エフ．ホフマン－ラ ロシュ アーゲー 大核酸の細胞内標的指向送達
EP3569618A1 (de) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisierender cd73-antikörper
EP3802602A1 (de) 2018-05-25 2021-04-14 Alector LLC Anti-sirpa-antikörper und verfahren zu ihrer verwendung
WO2019230868A1 (ja) 2018-05-30 2019-12-05 中外製薬株式会社 単ドメイン抗体含有リガンド結合分子
MX2020012940A (es) 2018-06-01 2021-03-25 Eisai R&D Man Co Ltd Metodos de uso de moduladores de empalme.
JOP20200268A1 (ar) 2018-06-01 2020-10-26 Eisai R&D Man Co Ltd تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
EP3805400A4 (de) 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit veränderter halbwertszeit im cytoplasma
US20210230300A1 (en) 2018-06-04 2021-07-29 Bayer Aktiengesellschaft Inhibitors of shp2
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
CN112585166A (zh) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
CN112384532B (zh) 2018-06-29 2025-01-10 艾利妥 抗SIRP-β1抗体及其使用方法
EP3818083A2 (de) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr-antikörpermoleküle und ihre verwendungen
WO2020007817A1 (en) 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
BR112021000727A2 (pt) 2018-07-20 2021-04-13 Surface Oncology, Inc. Composições anti-cd112r e métodos
HRP20260034T1 (hr) 2018-08-01 2026-02-27 Imcheck Therapeutics Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja
MX2021000827A (es) 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
CA3106537A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
EP3835321A4 (de) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha Anti-cd137-antigen-bindendes molekül und verwendung davon
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
US12253528B2 (en) 2018-09-05 2025-03-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating asthma and allergic diseases
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2020053125A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis
EP3849602A1 (de) 2018-09-10 2021-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombination eines her2/neu-antikörpers mit häm zur behandlung von krebs
EP3850008A1 (de) 2018-09-10 2021-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung eines inhibitors der ntsr1-aktivierung oder expression zur verhinderung von gewichtsverlust, muskelschwund und verringertem proteinblutspiegel bei probanden, die diese benötigen
WO2020056145A1 (en) 2018-09-14 2020-03-19 The Rockefeller University Anti-hiv antibody 10-1074 variants
WO2020058201A1 (en) 2018-09-17 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases
AR114732A1 (es) 2018-09-18 2020-10-07 Hoffmann La Roche Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
JP2022501332A (ja) 2018-09-19 2022-01-06 ジェネンテック， インコーポレイテッド 膀胱がんの治療方法および診断方法
EP3853251A1 (de) 2018-09-19 2021-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzung zur behandlung von krebserkrankungen mit resistenz gegen immun-checkpoint-therapie
KR102739487B1 (ko) 2018-09-21 2024-12-10 제넨테크, 인크. 3중-음성 유방암에 대한 진단 방법
BR112021005467A2 (pt) 2018-09-24 2021-06-22 Janssen Biotech, Inc. método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
US12473357B2 (en) 2018-09-25 2025-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of Th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
EP3861025A1 (de) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispezifische antigenbindende moleküle mit dreiwertiger bindung an cd40
NZ773887A (en) 2018-10-01 2024-11-29 Hoffmann La Roche Bispecific antigen binding molecules comprising anti-fap clone 212
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
WO2020070240A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
EP3860653A1 (de) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und systeme zur steuerung der agonistischen eigenschaften von variablen antikörperdomänen durch licht
EP3636657A1 (de) 2018-10-08 2020-04-15 Ablynx N.V. Chromatographiefreies antikörperreinigungsverfahren
JP2022512648A (ja) 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
TW202028244A (zh) 2018-10-09 2020-08-01 美商建南德克公司 用於確定突觸形成之方法及系統
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020079162A1 (en) 2018-10-18 2020-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inducing full ablation of hematopoiesis
MX2021004348A (es) 2018-10-18 2021-05-28 Genentech Inc Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
US12365722B2 (en) 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
JP7708662B2 (ja) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
EP3873519A1 (de) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antikörperformulierung
WO2020096959A1 (en) 2018-11-05 2020-05-14 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP3894427A1 (de) 2018-12-10 2021-10-20 Genentech, Inc. Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
PE20211473A1 (es) 2018-12-13 2021-08-05 Eisai Randd Man Co Ltd Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
WO2020120644A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
WO2020132231A1 (en) 2018-12-21 2020-06-25 Genentech, Inc. Methods of producing polypeptides using a cell line resistant to apoptosis
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
JP2022513495A (ja) 2018-12-21 2022-02-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
SG10202105788SA (en) 2018-12-21 2021-06-29 Hoffmann La Roche Antibodies binding to cd3
US11884719B2 (en) 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
BR112021012536A2 (pt) 2018-12-26 2021-09-14 City Of Hope Proteínas de ligação anti-ctla4 mascaradas ativáveis
CN113272327A (zh) 2018-12-30 2021-08-17 豪夫迈·罗氏有限公司 抗兔cd19抗体及其使用方法
EP3906415B1 (de) 2019-01-03 2026-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur verbesserung der cd8+-t-zellabhängigen immunantworten bei personen mit krebs
TW202515617A (zh) 2019-01-14 2025-04-16 美商建南德克公司 用於癌症療法之rna分子
MA54750A (fr) 2019-01-15 2021-11-24 Janssen Biotech Inc Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile
BR112021014267A2 (pt) 2019-01-23 2022-02-15 Janssen Biotech Inc Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
WO2020154410A1 (en) 2019-01-23 2020-07-30 Genentech, Inc. Methods of producing multimeric proteins in eukaryotic host cells
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
US20220073600A1 (en) 2019-01-28 2022-03-10 Maple Biotech Llc Methods for treating disease using psmp antagonists
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
SG11202107720UA (en) 2019-01-31 2021-08-30 Agency Science Tech & Res Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
US20220117911A1 (en) 2019-02-04 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
EP3921443A1 (de) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnose- und therapieverfahren für krebs
JP7150999B2 (ja) 2019-02-18 2022-10-11 エーティービー セラピューティクス 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法
WO2020169707A1 (en) 2019-02-21 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Foxo1 inhibitor for use in the treatment of latent virus infection
WO2020169698A1 (en) 2019-02-21 2020-08-27 F. Hoffmann-La Roche Ag Sensitization of cancer cells to tnf by bet inhibition
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
KR20210133237A (ko) 2019-02-27 2021-11-05 제넨테크, 인크. 항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
WO2020180591A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
US20220137054A1 (en) 2019-03-05 2022-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarkers and biotargets in renal cell carcinoma
MX2021010565A (es) 2019-03-08 2021-10-13 Genentech Inc Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
EP3938400B1 (de) 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22-antikörper und verfahren zur verwendung davon
TW202100556A (zh) 2019-03-14 2021-01-01 美商建南德克公司 使用her2 t細胞依賴性雙特異性抗體之治療
JP7662529B2 (ja) 2019-03-14 2025-04-15 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
CA3133381A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
KR20210141976A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 제조 방법
IL285909B2 (en) 2019-03-15 2023-04-01 Cartesian Therapeutics Inc Single-stranded variable segments directed against bcma
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
CN113613676A (zh) 2019-03-19 2021-11-05 中外制药株式会社 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
CN113631573B (zh) 2019-03-25 2024-06-04 国家医疗保健研究所 抗Tau抗体及其在制备用于治疗疾病的药物中的用途
WO2020201073A1 (en) 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
CN113631910A (zh) 2019-03-29 2021-11-09 豪夫迈·罗氏有限公司 细胞表面蛋白质相互作用的调节剂及其相关方法和组合物
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
EP3946377B1 (de) 2019-04-03 2025-12-10 Orega Biotech Kombinationstherapien auf basis von pd1- und il-17b-inhibitoren
EP3946416A2 (de) 2019-04-04 2022-02-09 Bayer Aktiengesellschaft Agonisten von adiponectin
EP3952898A1 (de) 2019-04-09 2022-02-16 Hospital for Special Surgery Proteinbindemittel für irhom2
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
WO2020208124A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Treatment of cancer using a cea cd3 bispecific antibody and a wnt signaling inhibitor
BR112021020867A2 (pt) 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
KR20220004028A (ko) 2019-04-26 2022-01-11 알로젠 테라퓨틱스 인코포레이티드 동종 car t 세포를 제조하는 방법
CA3135531A1 (en) 2019-04-30 2020-11-05 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
WO2020221796A1 (en) 2019-04-30 2020-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN114269376A (zh) 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 用抗pd-l1抗体治疗癌症的方法
US12150813B2 (en) 2019-05-10 2024-11-26 The University Of North Carolina At Chapel Hill Methods, systems, and computer readable media for generating super-resolution images of microvasculature using ultrasound
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
KR20220007136A (ko) 2019-05-14 2022-01-18 제넨테크, 인크. 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
MX2021013441A (es) 2019-05-15 2021-12-10 Chugai Pharmaceutical Co Ltd Molecula de union a antigenos, composicion farmaceutica y metodo.
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP3976067A1 (de) 2019-05-28 2022-04-06 Vib Vzw Cd8+-t-zellen ohne plexine und ihre anwendung zur krebsbehandlung
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
MA56015A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
US20220324959A1 (en) 2019-06-03 2022-10-13 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
MX2021014953A (es) 2019-06-04 2022-01-24 Janssen Biotech Inc Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23.
JPWO2020246563A1 (de) 2019-06-05 2020-12-10
CN114127277A (zh) 2019-06-05 2022-03-01 中外制药株式会社 蛋白酶底物和包含蛋白酶切割序列的多肽
CN114008713A (zh) 2019-06-07 2022-02-01 中外制药株式会社 信息处理系统、信息处理方法、程序、以及制备抗原结合分子或蛋白质的方法
US20200392229A1 (en) 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
JP7685957B2 (ja) 2019-06-20 2025-05-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル プロテアーゼネキシン－１に対する立体構造的な単一ドメイン抗体及びその使用
JP2022538075A (ja) 2019-06-26 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体結合ｃｅａ及び４－１ｂｂｌの融合
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
WO2021001289A1 (en) 2019-07-02 2021-01-07 F. Hoffmann-La Roche Ag Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
BR112022001045A2 (pt) 2019-07-22 2022-07-19 Seagen Inc Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
JP2022543551A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
MX2022001260A (es) 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
SG11202112491WA (en) 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
CN114401743A (zh) 2019-08-02 2022-04-26 法国国家健康和医学研究院 中和颗粒酶b用于向经历过心肌梗塞的受试者提供心脏保护
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2021050645A1 (en) 2019-09-12 2021-03-18 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
PE20221906A1 (es) 2019-09-18 2022-12-23 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso
CN114423454A (zh) 2019-09-20 2022-04-29 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体的给药
CN112625130B (zh) 2019-09-24 2023-08-29 财团法人工业技术研究院 抗-tigit抗体及使用之方法
EP4034560A1 (de) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müller-hemmungssubstanz-antikörper und verwendungen davon
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
EP4048693A1 (de) 2019-09-27 2022-08-31 F. Hoffmann-La Roche AG Dosieren zur behandlung mit anti-tigit- und anti-pd-l1-antagonist-antikörpern
US12590171B2 (en) 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof
WO2021063968A1 (en) 2019-09-30 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and composition for diagnosing chronic obstructive pulmonary disease
AU2020360849A1 (en) 2019-09-30 2022-04-14 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Protein binders to iRhom2 epitopes
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2021064180A1 (en) 2019-10-03 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
WO2021064184A1 (en) 2019-10-04 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
CN114945386A (zh) 2019-10-18 2022-08-26 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
WO2021078359A1 (en) 2019-10-21 2021-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of cubilin for the treatment of chronic kidney diseases
US20230220112A1 (en) 2019-10-28 2023-07-13 Monash University Antibodies for binding plasmin
WO2021092079A1 (en) 2019-11-05 2021-05-14 Acceleron Pharma Inc. Treatments for systemic sclerosis
AU2020381349A1 (en) 2019-11-05 2022-04-28 F. Hoffmann-La Roche Ag Treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide
AU2020378330A1 (en) 2019-11-06 2022-05-12 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for treatment of hematologic cancers
JP7657213B2 (ja) 2019-11-07 2025-04-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法
EP4058469A1 (de) 2019-11-12 2022-09-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Neuer serologischer marker für die latente form von toxoplasmose
EP4058593A4 (de) 2019-11-12 2023-11-15 Foundation Medicine, Inc. Verfahren zum nachweis eines fusionsgens, das für ein neoantigen codiert
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
JP2023503851A (ja) 2019-11-15 2023-02-01 プライアント・セラピューティクス・インコーポレイテッド インテグリン活性化のための組成物および方法
CN114728065A (zh) 2019-11-26 2022-07-08 上海岸迈生物科技有限公司 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
WO2021110796A1 (en) 2019-12-04 2021-06-10 Bayer Aktiengesellschaft Inhibitors of shp2
US12577324B2 (en) 2019-12-09 2026-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity to HER4 and uses thereof
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
JP2023506465A (ja) 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CR20220256A (es) 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
CN115298213A (zh) 2019-12-19 2022-11-04 奎多公司 单克隆抗体融合
WO2021119761A1 (en) 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
CN114829408B (zh) 2019-12-20 2024-01-26 山东博安生物技术股份有限公司 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
EP4081294A2 (de) 2019-12-23 2022-11-02 Genentech, Inc. Apolipoprotein l1-spezifische antikörper und verwendungsverfahren
US20230074385A1 (en) 2019-12-23 2023-03-09 Eisai R&D Management Co., Ltd. Method for producing eribulin-based antibody-drug conjugate
MY202559A (en) 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
MX2022008214A (es) 2020-01-09 2022-08-08 Hoffmann La Roche Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
EP4090770A1 (de) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur behandlung von melanom
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
MX2022009391A (es) 2020-01-31 2022-09-26 Genentech Inc Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Tat peptide binding proteins and uses thereof
WO2021160154A1 (zh) 2020-02-10 2021-08-19 上海诗健生物科技有限公司 Cldn18.2抗体及其用途
US20230096452A1 (en) 2020-02-10 2023-03-30 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CN113248611B (zh) 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
EP4118120A4 (de) 2020-03-12 2024-04-17 Immune-ONC Therapeutics, Inc. Neuartige anti-lilrb4-antikörper und derivatprodukte
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TWI867190B (zh) 2020-03-19 2024-12-21 美商建南德克公司 同功型選擇性抗-TGF-β抗體及其使用方法
IL296528A (en) 2020-03-24 2022-11-01 Genentech Inc Tie2-binding agents and methods of use
KR20220159426A (ko) 2020-03-26 2022-12-02 제넨테크, 인크. 감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
JP2023519962A (ja) 2020-03-31 2023-05-15 アレクトル エルエルシー 抗ｍｅｒｔｋ抗体及びその使用方法
AU2021250446A1 (en) 2020-03-31 2022-11-17 Biotalys NV Anti-fungal polypeptides
US20230121511A1 (en) 2020-03-31 2023-04-20 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
WO2021202235A1 (en) 2020-04-01 2021-10-07 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
EP4127724A1 (de) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutische und diagnostische verfahren für krebs
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
PH12022552436A1 (en) 2020-04-15 2024-01-03 Hoffmann La Roche Immunoconjugates
JP2023523600A (ja) 2020-04-22 2023-06-06 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド ヒトプログラム細胞死リガンド１（ｐｄ－ｌ１）を標的とする単一可変ドメイン抗体およびその誘導体
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
EP4143345A1 (de) 2020-04-28 2023-03-08 Genentech, Inc. Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
EP4146283A1 (de) 2020-05-03 2023-03-15 Levena (Suzhou) Biopharma Co., Ltd. Antikörper-wirkstoff-konjugate (adcs) mit einem anti-trop-2-antikörper, zusammensetzungen mit solchen adcs sowie verfahren zur herstellung und verwendung davon
EP4146273A4 (de) 2020-05-05 2024-07-31 Janssen Biotech, Inc. Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
WO2021224401A1 (en) 2020-05-07 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for determining a reference range of β-galactose exposure platelet
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
TW202200622A (zh) 2020-05-13 2022-01-01 瑞士商天演藥業公司 用於治療癌症之組成物及方法
EP4149964A2 (de) 2020-05-15 2023-03-22 Apogenix AG Multispezifische immunmodulatoren
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
JP2023527169A (ja) 2020-05-20 2023-06-27 タケダ ワクチン，インコーポレイテッド 抗原の効力を決定するための方法
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン，インコーポレイテッド ジカウイルス特異的抗体の検出方法
CA3182333A1 (en) 2020-05-20 2021-11-25 Institut Curie Single domain antibodies and their use in cancer therapies
US20230183675A1 (en) 2020-05-20 2023-06-15 Institut Curie Synthetic Single Domain Library
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
CN116323665A (zh) 2020-05-29 2023-06-23 23和我公司 抗cd200r1抗体及其使用方法
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
WO2021245224A1 (en) 2020-06-05 2021-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating ocular diseases
AR122546A1 (es) 2020-06-05 2022-09-21 Eisai R&D Man Co Ltd Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
MX2022015206A (es) 2020-06-08 2023-01-05 Hoffmann La Roche Anticuerpos anti-hbv y metodos de uso.
IL298878A (en) 2020-06-11 2023-02-01 Genentech Inc Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
US11981932B2 (en) 2020-06-17 2024-05-14 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
CN115916348A (zh) 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
CA3177239A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific antibodies
JP2023530961A (ja) 2020-06-19 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に結合する抗体
BR112022025856A2 (pt) 2020-06-19 2023-01-10 Hoffmann La Roche Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
KR20230025673A (ko) 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 CD3 및 FolR1에 결합하는 항체
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
JP2023531222A (ja) 2020-06-22 2023-07-21 アルミラル・ソシエダッド・アノニマ 抗ｉｌ－３６抗体およびその使用方法
CN115702168A (zh) 2020-06-23 2023-02-14 豪夫迈·罗氏有限公司 靶向Her2的激动性CD28抗原结合分子
US20220041672A1 (en) 2020-06-24 2022-02-10 Genentech, Inc. Apoptosis resistant cell lines
CN115916830A (zh) 2020-06-25 2023-04-04 豪夫迈·罗氏有限公司 抗cd3/抗cd28双特异性抗原结合分子
KR20230030644A (ko) 2020-06-29 2023-03-06 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
WO2022002112A1 (en) 2020-07-01 2022-01-06 Shandong Boan Biotechnology Co., Ltd. Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
EP4178616A4 (de) 2020-07-13 2024-07-24 Janssen Biotech, Inc. Sicheres und wirksames verfahren zur behandlung von psoriasisarthritis mit anti-il23-spezifischem antikörper
CA3188000A1 (en) 2020-07-13 2022-01-20 Genentech, Inc. Cell-based methods for predicting polypeptide immunogenicity
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
EP4182348A1 (de) 2020-07-17 2023-05-24 Genentech, Inc. Anti-notch2-antikörper und verfahren zur verwendung
PE20231104A1 (es) 2020-07-21 2023-07-19 Genentech Inc Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CA3190230A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
WO2022029080A1 (en) 2020-08-03 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
CN115836122A (zh) 2020-08-07 2023-03-21 基因泰克公司 用于预测多肽免疫原性的基于t细胞的方法
EP4192481A4 (de) 2020-08-10 2024-09-11 Janssen Biotech, Inc. Materialien und verfahren zur herstellung von biomanipulierten virusspezifischen lymphozyten
CA3187245A1 (en) 2020-08-17 2022-02-24 Sebastien Mercx Recombinant immunotoxin comprising a ribotoxin or rnase
CN114106173A (zh) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
EP4204806A1 (de) 2020-08-31 2023-07-05 Genentech, Inc. Verfahren zur herstellung von antikörpern
US11970539B2 (en) 2020-09-14 2024-04-30 Ichnos Sciences SA Antibodies that bind to IL1RAP and uses thereof
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
EP4216943A1 (de) 2020-09-24 2023-08-02 Vib Vzw Kombination von p2y6-inhibitoren und immuncheckpoint-inhibitoren
CN116322691A (zh) 2020-09-24 2023-06-23 豪夫迈·罗氏有限公司 T细胞双特异性抗体相关不良反应的预防或减轻
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
MX2023003404A (es) 2020-09-28 2023-03-31 Seagen Inc Anticuerpos anti-l1vi humanizados para el tratamiento del cancer.
WO2022072523A1 (en) 2020-09-30 2022-04-07 Seagen Inc. Uveal melanoma treatment using sea-cd40
KR20230082632A (ko) 2020-10-05 2023-06-08 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
US20240230647A9 (en) 2020-10-09 2024-07-11 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
AR123855A1 (es) 2020-10-20 2023-01-18 Genentech Inc Anticuerpos anti-mertk conjugados con peg y métodos de uso
IL300024A (en) 2020-10-20 2023-03-01 Hoffmann La Roche Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
JP7633397B2 (ja) 2020-10-21 2025-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼の疾患の処置のための二重特異性抗ＶＥＧＦ及び抗ＴｒｋＢ結合分子
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
US20230391863A1 (en) 2020-10-23 2023-12-07 Hq Han Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
CN116635419A (zh) 2020-10-30 2023-08-22 豪夫迈·罗氏有限公司 使用CEA CD3双特异性抗体和TGFβ信号传导抑制剂的癌症治疗
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
KR20230100732A (ko) 2020-11-04 2023-07-05 제넨테크, 인크. 항-cd20/항-cd3 이중특이성 항체의 피하 투여
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
EP4240761A1 (de) 2020-11-05 2023-09-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von il-6-inhibitoren zur behandlung des akuten brustsyndroms bei patienten mit sichelzellanämie
WO2022101120A1 (en) 2020-11-10 2022-05-19 F. Hoffmann-La Roche Ag Prevention or mitigation of t-cell engaging agent-related adverse effects
WO2022101481A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
PE20231556A1 (es) 2020-11-16 2023-10-03 Hoffmann La Roche Glucoformas de fab ricas en manosa
JP2023549316A (ja) 2020-11-16 2023-11-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法
BR112023009875A2 (pt) 2020-11-23 2024-02-06 Genentech Inc Métodos para tratar um indivíduo com uma infecção por sars-cov-2, para reduzir a ligação de sars-cov-2 a uma célula, para diminuir a infecção por sars-cov-2 e para identificar um modulador, métodos de profilaxia, moduladores isolados, usos e antagonistas
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
EP4251191A1 (de) 2020-11-27 2023-10-04 Genentech, Inc. Verfahren zur modulation der interaktionen der oberfläche von wirtszellen mit dem humanen cytomegalovirus
WO2022119805A1 (en) 2020-12-01 2022-06-09 Genentech, Inc. Biological vesicles displaying cell surface proteins and methods related to same
WO2022120352A1 (en) 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用
CN117015386A (zh) 2020-12-21 2023-11-07 旗舰创业创新五公司 细胞周转因子用于增加组织再生的用途
WO2022148732A1 (en) 2021-01-06 2022-07-14 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
CA3204628A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
TW202245844A (zh) 2021-01-13 2022-12-01 紀念斯隆凱特琳癌症中心 抗dll3抗體-藥物結合物
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
JP2024505428A (ja) 2021-01-14 2024-02-06 アンスティテュ キュリー Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
JP2024505636A (ja) 2021-01-15 2024-02-07 ザ ロックフェラー ユニバーシティー 抗ｓａｒｓ－ｃｏｖ－２中和抗体
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4281484B1 (de) 2021-01-22 2026-03-18 Hangzhou Baikai Biopharmaceutical Co., Ltd Anti-her-2/trop-2-konstrukte und verwendungen davon
US20230390411A1 (en) 2021-01-28 2023-12-07 Nanjing Chempion Biotechnology Co., Ltd. Conjugate and use thereof
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
CA3209052A1 (en) 2021-02-19 2022-08-25 Rafael Cristian CASELLAS Single domain antibodies that neutralize sars-cov-2
US12180521B2 (en) 2021-02-19 2024-12-31 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
JP2024512253A (ja) 2021-02-22 2024-03-19 ジェネンテック， インコーポレイテッド 宿主細胞の表面とヘルペスウイルスとの相互作用を調節するための方法
MX2023009946A (es) 2021-02-26 2023-09-04 Bayer Ag Inhibidores de il-11 o il-11ra para uso en el tratamiento de sangrado uterino anormal.
WO2022184594A1 (en) 2021-03-01 2022-09-09 Scirhom Gmbh Humanized antibodies against irhom2
WO2022187270A1 (en) 2021-03-01 2022-09-09 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301781A1 (de) 2021-03-01 2024-01-10 Xilio Development, Inc. Kombination von maskierten ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
US20240181073A1 (en) 2021-03-03 2024-06-06 Sorrento Therapeutics, Inc. Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
MX2023010705A (es) 2021-03-12 2023-11-22 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
JP2024512377A (ja) 2021-03-12 2024-03-19 ジェネンテック， インコーポレイテッド 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
BR112023018400A2 (pt) 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
EP4308157A1 (de) 2021-03-15 2024-01-24 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von lupus nephritis
AU2022238849A1 (en) 2021-03-17 2023-08-31 Receptos Llc Methods of treating atopic dermatitis with anti il-13 antibodies
EP4308133A4 (de) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. Manipulierte chimäre fusionsproteinzusammensetzungen und verfahren zur verwendung davon
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
WO2022194908A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2024512002A (ja) 2021-03-18 2024-03-18 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
KR20240012352A (ko) 2021-03-23 2024-01-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) T 세포 림프종의 진단 및 치료 방법
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
US20240174744A1 (en) 2021-03-29 2024-05-30 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
EP4314032A1 (de) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-aktivierte polypeptide
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
EP4320153A1 (de) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von anaplastischem grosszelligem lymphom
IL307267A (en) 2021-04-14 2023-11-01 Villaris Therapeutics Inc ANTI-CD122 antibodies and their uses
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
US20240368605A1 (en) 2021-04-19 2024-11-07 Institut National de la Santé et de la Recherche Médicale Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
CA3215965A1 (en) 2021-04-19 2022-10-27 Amy Shen Modified mammalian cells
WO2022223651A1 (en) 2021-04-23 2022-10-27 F. Hoffmann-La Roche Ag Prevention or mitigation of nk cell engaging agent-related adverse effects
US20240158861A1 (en) 2021-04-23 2024-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
MX2023012699A (es) 2021-04-30 2023-11-21 Hoffmann La Roche Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
AU2022272235A1 (en) 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
KR20240007184A (ko) 2021-05-12 2024-01-16 제넨테크, 인크. 미만성 거대 b세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
AU2022273303A1 (en) 2021-05-14 2023-11-02 Genentech, Inc. Agonists of trem2
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
TW202314247A (zh) 2021-05-25 2023-04-01 美商思進公司 量化抗cd40抗體之方法
EP4348257B1 (de) 2021-05-26 2026-02-04 Genentech, Inc. Verfahren zur modulation der interaktionen der oberfläche von wirtszellen mit dem humanen cytomegalovirus
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
US20240270853A1 (en) 2021-06-04 2024-08-15 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
BR112023025194A2 (pt) 2021-06-04 2024-02-27 Boehringer Ingelheim Int Anticorpos anti-sirp-alfa
AU2022289684A1 (en) 2021-06-09 2023-10-05 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
US20240279341A1 (en) 2021-06-16 2024-08-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗ＭｅｒＴＫ抗体及びその使用方法
EP4355778A1 (de) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Neue trispezifische bindungsmoleküle
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
TWI864408B (zh) 2021-06-25 2024-12-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
AU2022299846B2 (en) 2021-06-25 2024-08-15 Chugai Seiyaku Kabushiki Kaisha Anti–ctla-4 antibody
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4363449A2 (de) 2021-07-02 2024-05-08 Genentech, Inc. Verfahren und zusammensetzungen zur behandlung von krebs
AU2022308201A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
IL309987A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-IL12/IL23 antibody compositions
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
EP4512826A3 (de) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimere proteinkomplexe und verwendungen davon
EP4370550A1 (de) 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung von il-36 inhibitoren zur behandlung des netherton syndroms
CA3224853A1 (en) 2021-07-14 2023-01-19 Gautham GAMPA Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
JP2024526880A (ja) 2021-07-22 2024-07-19 ジェネンテック， インコーポレイテッド 脳標的化組成物及びその使用方法
JP2024528631A (ja) 2021-07-22 2024-07-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロ二量体Ｆｃドメイン抗体
AU2022317820A1 (en) 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
KR20240038768A (ko) 2021-07-30 2024-03-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키메라 단백질 및 면역치료 방법
EP4377348A1 (de) 2021-07-30 2024-06-05 Seagen Inc. Behandlung von krebs
EP4380980A1 (de) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispezifische antikörper und verfahren zur verwendung
EP4384553A1 (de) 2021-08-13 2024-06-19 Genentech, Inc. Dosierung für antitryptase-antikörper
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
TW202313695A (zh) 2021-09-15 2023-04-01 法商感應檢查療法公司 抗ｂｔｎ３ａ抗體在製備用於治療腫瘤的藥物的用途
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
JPWO2023053282A1 (de) 2021-09-29 2023-04-06
IL311655A (en) 2021-09-30 2024-05-01 Seagen Inc B7-H4 antibody-drug conjugates for cancer treatment
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
JP2024538677A (ja) 2021-10-04 2024-10-23 タケダ ワクチン，インコーポレイテッド ノロウイルス反応性抗体を決定する方法
US20230190806A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Methods of treating metastatic lesions and compositions thereof
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
TW202333781A (zh) 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑
AU2022362681A1 (en) 2021-10-14 2024-04-04 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
EP4419558A1 (de) 2021-10-19 2024-08-28 Alector LLC Anti-cd300lb-antikörper und verfahren zur verwendung davon
JP2024539893A (ja) 2021-10-27 2024-10-31 イムチェック セラピューティクス エスエーエス 感染性障害を治療する方法で使用するためのブチロフィリン（ｂｔｎ）３ａ活性化抗体
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
TW202325742A (zh) 2021-11-01 2023-07-01 瑞士商赫孚孟拉羅股份公司 使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
US20240426823A1 (en) 2021-11-03 2024-12-26 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating triple negative breast cancer (tnbc)
EP4448108A1 (de) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive zelltherapiekombinationsbehandlung und zusammensetzungen davon
EP4429769A1 (de) 2021-11-09 2024-09-18 Sensei Biotherapeutics, Inc. Anti-vista-antikörper und verwendungen davon
EP4430072A1 (de) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33-antikörper und verwendungen davon
EP4433501A1 (de) 2021-11-15 2024-09-25 Janssen Biotech, Inc. Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
KR20240102971A (ko) 2021-11-16 2024-07-03 제넨테크, 인크. 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물
WO2023088889A1 (en) 2021-11-16 2023-05-25 Apogenix Ag CD137 ligands
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
ES3039688T3 (en) 2021-11-25 2025-10-23 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
EP4441094A1 (de) 2021-11-29 2024-10-09 Ose Immunotherapeutics Spezifische antagonistische anti-sirpg-antikörper
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
EP4448095A1 (de) 2021-12-14 2024-10-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Abreicherung von nk-zellen zur behandlung von postischämischer kardialer remodellierung
JP2024546589A (ja) 2021-12-14 2024-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｍａｇｅ－ａ４×ｃｄ３二重特異性抗体及び４－１ｂｂ（ｃｄ１３７）アゴニストを使用したがんの治療
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
CA3241407A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
TW202346346A (zh) 2021-12-23 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途
EP4209508A1 (de) 2022-01-11 2023-07-12 Centre national de la recherche scientifique Nanokörpern für das deneddylierende enzym nedp1
US20230322958A1 (en) 2022-01-19 2023-10-12 Genentech, Inc. Anti-Notch2 Antibodies and Conjugates and Methods of Use
EP4471005A4 (de) 2022-01-24 2025-11-19 Beijing Chempion Biotechnology Co Ltd Konjugat und verwendung davon
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
WO2023144235A1 (en) 2022-01-27 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
EP4469159A1 (de) 2022-01-27 2024-12-04 The Rockefeller University Breit neutralisierende anti-sars-cov-2-antikörper gegen die n-terminale domäne des spike-proteins und verfahren zur verwendung davon
EP4471065A4 (de) 2022-01-29 2025-11-26 Carsgen Life Sciences Co Ltd Gprc5d-antikörper und verwendung davon
US20250067745A1 (en) 2022-01-31 2025-02-27 Institut National de la Santé et de la Recherche Médicale Cd38 as a biomarker and biotarget in t-cell lymphomas
IL314969A (en) 2022-02-17 2024-10-01 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
EP4231017A1 (de) 2022-02-17 2023-08-23 Promise Proteomics Nachweis und quantifizierung von anti-arzneimittel-antikörpern und anti-selbst-antikörpern
EP4489790A1 (de) 2022-03-10 2025-01-15 Vivasor, Inc. Antikörper-wirkstoff-konjugate und verwendungen davon
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
CR20240375A (es) 2022-03-11 2025-01-06 Mablink Bioscience Conjugados anticuerpo-fármaco y sus usos
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2025514610A (ja) 2022-03-25 2025-05-09 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｍｓｌｎ抗体及び使用方法
JP2025511000A (ja) 2022-03-28 2025-04-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト インターフェロンガンマバリアントおよびこれを含む抗原結合分子
AU2023247337A1 (en) 2022-03-30 2024-11-14 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
IL315770A (en) 2022-04-01 2024-11-01 Genentech Inc Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
JP2025514669A (ja) 2022-04-11 2025-05-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍の診断及び処置のための方法
JP2025512327A (ja) 2022-04-12 2025-04-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンベースの抗体－薬物コンジュゲート及び使用方法
CN119013300A (zh) 2022-04-13 2024-11-22 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
TWI882313B (zh) 2022-04-13 2025-05-01 美商建南德克公司 治療性蛋白質之醫藥組成物及使用方法
US20250249278A1 (en) 2022-04-14 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
US20250296996A1 (en) 2022-04-29 2025-09-25 Broadwing Bio, Inc. Angiopoietin-related protein 7-specific antibodies and uses thereof
US20250346653A1 (en) 2022-04-29 2025-11-13 Broadwing Bio Inc. Bispecific antibodies and method of treating ocular disease
WO2023212293A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof
CA3257258A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-Ly6E antibodies, immunoconjugates, and their uses
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
CN119317641A (zh) 2022-05-11 2025-01-14 基因泰克公司 针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
US20250282874A1 (en) 2022-05-17 2025-09-11 Suzhou Transcenta Therapeutics Co., Ltd. Bifunctional protein, and preparation thereof and use thereof
EP4526342A1 (de) 2022-05-18 2025-03-26 Janssen Biotech, Inc. Verfahren zur bewertung und behandlung von psoriasisarthritis mit il23-antikörper
US20230416412A1 (en) 2022-05-31 2023-12-28 Hoffmann-La Roche Inc. Prevention or mitigation of t-cell engaging agent-related adverse effects
EP4537107A2 (de) 2022-06-07 2025-04-16 Genentech, Inc. Verfahren zur bestimmung der wirksamkeit einer lungenkrebsbehandlung mit einem anti-pd-l1-antagonisten und einem anti-tigit-antagonisten-antikörper
EP4536198A1 (de) 2022-06-09 2025-04-16 Institut National de la Santé et de la Recherche Médicale Verwendung von endothelinrezeptor-typ-b-agonisten zur behandlung von aortenklappenstenose
CN117285643A (zh) 2022-06-16 2023-12-26 清华大学 一种相变调节套件及其用途
CN117285644A (zh) 2022-06-16 2023-12-26 清华大学 一种相变调节元件及其用途
EP4299124A1 (de) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2-nanokörper zur verwendung als biomolekültransporter
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
WO2024008274A1 (en) 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
JP2025521677A (ja) 2022-07-06 2025-07-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 増殖性糸球体腎炎を処置するための方法
WO2024013234A1 (en) 2022-07-13 2024-01-18 Institut National de la Santé et de la Recherche Médicale Methods for diagnosis, prognosis, stratification and treating of myocarditis
JP2025523020A (ja) 2022-07-13 2025-07-17 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
IL317689A (en) 2022-07-15 2025-02-01 Boehringer Ingelheim Int Binding molecules for cancer treatment
CA3261510A1 (en) 2022-07-19 2024-01-25 F. Hoffmann-La Roche Ag DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
EP4558128A1 (de) 2022-07-21 2025-05-28 Institut National de la Santé et de la Recherche Médicale Mit einem erv syncitin funktionalisierte extrazelluläre vesikel und verwendungen davon zur frachtabgabe
AR129991A1 (es) 2022-07-22 2024-10-23 Bristol Myers Squibb Co Anticuerpos que se unen a la pad4 humana y usos de los mismos
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
CA3262611A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. IMPROVED TRANSFER OF GENETIC INSTRUCTIONS TO EFFECTOR IMMUNE CELLS
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
TW202415679A (zh) 2022-07-29 2024-04-16 美商阿列克特有限責任公司 抗ｇｐｎｍｂ抗體及其使用方法
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
US20260060969A1 (en) 2022-08-04 2026-03-05 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
EP4568997A1 (de) 2022-08-08 2025-06-18 ATB Therapeutics Humanisierte antikörper gegen cd79b
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
EP4573553A1 (de) 2022-08-15 2025-06-25 ABSCI Corporation Spezifische zellanreicherung mit quantitativer affinitätsaktivität
EP4573119A1 (de) 2022-08-17 2025-06-25 Institut National de la Santé et de la Recherche Médicale Verbesserte anti-albumin-nanokörper und ihre verwendungen
JP2025528459A (ja) 2022-08-31 2025-08-28 アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル（インセルム） より効率的なｃａｒ－ｔ細胞を生成する方法
JP2025531738A (ja) 2022-09-01 2025-09-25 ジェネンテック， インコーポレイテッド 膀胱がんの治療方法及び診断方法
EP4584291A1 (de) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antikörper mit spezifität gegen ltbp2 und verwendungen davon
US20260035468A1 (en) 2022-09-12 2026-02-05 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
JP2025534285A (ja) 2022-09-29 2025-10-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ポリペプチド
WO2024074498A1 (en) 2022-10-04 2024-04-11 Imcheck Therapeutics Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
TW202421664A (zh) 2022-10-07 2024-06-01 美商建南德克公司 用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法
US20260077045A1 (en) 2022-10-07 2026-03-19 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
EP4602372A1 (de) 2022-10-12 2025-08-20 Institut National de la Santé et de la Recherche Médicale Cd81 als biomarker und biotarget bei t-zell-malignitäten
EP4605077A1 (de) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Gegen den melanocortin-4-rezeptor gerichtete aminosäuresequenzen und polypeptide damit zur behandlung von mc4r-bedingten erkrankungen und störungen
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
WO2024102734A1 (en) 2022-11-08 2024-05-16 Genentech, Inc. Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
EP4615874A1 (de) 2022-11-10 2025-09-17 Immuvia Inc Zytotoxische bispezifische antikörper mit bindung an dr5 und muc16 und verwendungen davon
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
CN120265651A (zh) 2022-11-25 2025-07-04 中外制药株式会社 用于生产蛋白质的方法
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024115349A1 (en) 2022-11-29 2024-06-06 F. Hoffmann-La Roche Ag Improved cancer immunotherapy
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
WO2024120516A1 (zh) 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
CN120693406A (zh) 2022-12-12 2025-09-23 基因泰克公司 优化多肽唾液酸含量
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024126685A1 (en) 2022-12-15 2024-06-20 Institut National de la Santé et de la Recherche Médicale Single-domain antibody targeting von wilebrand factor a3-domain
KR20250134734A (ko) 2022-12-16 2025-09-11 페온 테라퓨틱스 리미티드 Cub 도메인-함유 단백질 1(cdcp1)에 대한 항체 및 이의 용도
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
WO2024131962A1 (zh) 2022-12-23 2024-06-27 成都恩沐生物科技有限公司 新型抗gprc5d抗体
CN120476149A (zh) 2022-12-23 2025-08-12 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
WO2024143442A1 (ja) 2022-12-27 2024-07-04 中外製薬株式会社 会合が制御されたポリペプチド
WO2024141955A1 (en) 2022-12-28 2024-07-04 BioNTech SE Rna compositions targeting hiv
WO2024145551A1 (en) 2022-12-29 2024-07-04 Biotalys NV Agrochemical compositions
EP4646270A2 (de) 2023-01-06 2025-11-12 Alector LLC Anti-il18-bindende proteinantikörper und verfahren zur verwendung davon
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024149821A1 (en) 2023-01-13 2024-07-18 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine
WO2024155807A1 (en) 2023-01-18 2024-07-25 Genentech, Inc. Multispecific antibodies and uses thereof
CR20250279A (es) 2023-01-20 2025-08-25 Boehringer Ingelheim Int Proteínas de fusión fc de il-12
CN120569216A (zh) 2023-01-20 2025-08-29 巴斯夫欧洲公司 稳定型生物聚合物组合物、其制造和用途
EP4651864A2 (de) 2023-01-20 2025-11-26 Genentech, Inc. Funktionen und interaktionen der e3-ligase-familie
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
TW202436339A (zh) 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
EP4659023A1 (de) 2023-02-03 2025-12-10 Immusmol SAS Verfahren zur vorhersage des erfolgs einer krebstherapie
JP2026506893A (ja) 2023-02-23 2026-02-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用
EP4669350A1 (de) 2023-02-24 2025-12-31 Institut National de la Santé et de la Recherche Médicale Verfahren zur behandlung von endometriose
IL322887A (en) 2023-02-27 2025-10-01 Suzhou Suncadia Biopharmaceuticals Co Ltd Anti-DLL3 antibody, antibody-drug conjugate and pharmaceutical use thereof
WO2024182569A2 (en) 2023-02-28 2024-09-06 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
JP2026509243A (ja) 2023-03-10 2026-03-17 ジェネンテック， インコーポレイテッド プロテアーゼとの融合およびその使用
JP2026510584A (ja) 2023-03-13 2026-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１－ｌａｇ３二重特異性抗体およびｈｌａ－ｇ ｔ細胞二重特異性抗体を用いる併用療法
EP4680638A1 (de) 2023-03-13 2026-01-21 F. Hoffmann-La Roche AG Behandlung von krebs mit einem bispezifischen anti-hla-g/anti-cd3-antikörper und a4-1bb (cd137)-agonist
CN121194989A (zh) 2023-03-30 2025-12-23 272生物有限公司 GnRH结合多肽及其用途
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
EP4687997A2 (de) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antikörper-wirkstoff-konjugate und verwendungen davon
EP4687995A1 (de) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antikörper-wirkstoff-konjugate und verwendungen davon
EP4687996A1 (de) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antikörper-wirkstoff-konjugate und verwendungen davon
EP4698230A2 (de) 2023-04-17 2026-02-25 Peak Bio, Inc. Antikörper und antikörper-wirkstoff-konjugate sowie verfahren zur verwendung und synthetische verfahren und zwischenprodukte
TW202506731A (zh) 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AR132623A1 (es) 2023-05-08 2025-07-16 Hoffmann La Roche PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
IL324490A (en) 2023-05-10 2026-01-01 Genentech Inc Methods and preparations for treating cancer
EP4709753A1 (de) 2023-05-11 2026-03-18 Vib Vzw Slc4a4/nbce1-inhibitoren
CN121263435A (zh) 2023-05-16 2026-01-02 豪夫迈·罗氏有限公司 Pd-1调节的il-2免疫细胞因子及其用途
EP4713003A1 (de) 2023-05-17 2026-03-25 Institut National de la Santé et de la Recherche Médicale Lipc-variante zur behandlung von hypercholesterinämie und atherosklerotischer kardiovaskulärer erkrankung
IL324547A (en) 2023-05-18 2026-01-01 Clade Therapeutics Inc Inhibition of natural killer cell cytotoxicity against cellular therapies
TW202509075A (zh) 2023-05-19 2025-03-01 德商百靈佳殷格翰國際股份有限公司 T細胞銜接蛋白治療癌症之用途
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
TW202448933A (zh) 2023-05-31 2024-12-16 美商建南德克公司 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
EP4720121A1 (de) 2023-06-01 2026-04-08 F. Hoffmann-La Roche AG Immunstimulierende antigenbindende moleküle, die spezifisch an bcma binden
EP4720120A1 (de) 2023-06-01 2026-04-08 F. Hoffmann-La Roche AG Bispezifische antikörper gegen bcma und cd28
EP4720122A1 (de) 2023-06-05 2026-04-08 Pure Biologics Spólka Akcyjna Anti-garp-antikörper und verfahren zur verwendung
EP4719367A1 (de) 2023-06-05 2026-04-08 Pure Biologics Spólka Akcyjna Anti-ror1-antikörper und verfahren zur verwendung
EP4725969A1 (de) 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Komplementäres bispezifisches anti-her2-antikörper-wirkstoff-konjugat, herstellungsverfahren dafür und verwendung davon
EP4477236A1 (de) 2023-06-14 2024-12-18 Inatherys Kombinationstherapie zur behandlung eines tumors mit adc mit anti-cd71-antikörpern und bh3-mimetika
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
KR20260026086A (ko) 2023-06-21 2026-02-25 에프. 호프만-라 로슈 아게 Fap 표적화 림포톡신 베타 수용체 작용제를 이용한 조합 요법
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
EP4731255A1 (de) 2023-06-22 2026-04-29 Genentech, Inc. Behandlung von multiplem myelom
TW202502809A (zh) 2023-06-22 2025-01-16 美商建南德克公司 抗體及其用途
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
KR20260036321A (ko) 2023-07-05 2026-03-16 씨에스엘 이노베이션 피티와이 엘티디 겸상적혈구병의 합병증을 치료하거나 예방하는 방법
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025017186A1 (en) 2023-07-20 2025-01-23 Institut National de la Santé et de la Recherche Médicale Extracellular vesicles functionalized with a tethering system for cargo delivery
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
CN121712799A (zh) 2023-07-26 2026-03-20 豪夫迈·罗氏有限公司 与cd3结合的抗体
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
CN121866336A (zh) 2023-08-03 2026-04-14 百欧恩泰欧洲股份公司 靶向hiv的rna组合物
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
EP4512243A1 (de) 2023-08-21 2025-02-26 Kymab Limited Bindungsmoleküle
AU2024329275A1 (en) 2023-08-23 2026-03-19 Granular Therapeutics Limited Anti-cd203c antibody conjugates and uses thereof
WO2025049277A1 (en) 2023-08-25 2025-03-06 Genentech, Inc. Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
AU2024343373A1 (en) 2023-09-14 2026-02-12 F. Hoffmann-La Roche Ag Antibody formulation
WO2025056807A1 (en) 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
US12122842B1 (en) 2023-09-27 2024-10-22 R&D Systems, Inc. Human CD30-specific binding proteins and uses thereof
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
TW202535460A (zh) 2023-10-06 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗ＳＩＲＰ－α抗體用於治療癌症之用途
TW202535461A (zh) 2023-10-06 2025-09-16 德商百靈佳殷格翰國際股份有限公司 使用抗ｓｉｒｐａ抗體治療肝臟疾病或病症
TW202517301A (zh) 2023-10-06 2025-05-01 美商思進公司 用ｂ７－ｈ４抗體－藥物結合物治療晚期實體腫瘤之方法
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
TW202518024A (zh) 2023-10-13 2025-05-01 日商衛材R&D企管股份有限公司 抗體－藥物軛合物代謝物
TW202530697A (zh) 2023-10-13 2025-08-01 日商衛材R&D企管股份有限公司 用於基於艾日布林之抗體－藥物結合物之生物標記及使用方法
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025106634A1 (en) 2023-11-17 2025-05-22 Genentech, Inc. Mcl-1 inhibitor compounds and use in antibody drug conjugates
WO2025109043A2 (en) 2023-11-22 2025-05-30 Institut National de la Santé et de la Recherche Médicale Use of neutralizing anti-agr2 antibodies for preventing resistance to chemotherapy
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
WO2025114411A1 (en) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale New method to treat brain or neurologic disorders
WO2025114699A1 (en) 2023-11-30 2025-06-05 Cytomos Limited Cell selection
WO2025129010A1 (en) 2023-12-14 2025-06-19 Genentech, Inc. Methods of structure determination using antibodies
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025132833A1 (en) 2023-12-20 2025-06-26 Institut National de la Santé et de la Recherche Médicale Anti trypsin-3 single domain antibody
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
EP4574981A1 (de) 2023-12-22 2025-06-25 Biotalys NV Anti-fungale vhh-antikörper
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025144700A1 (en) 2023-12-27 2025-07-03 Absci Corporation Nanobody library screening using bacterial surface display
WO2025153608A1 (en) 2024-01-18 2025-07-24 Institut National de la Santé et de la Recherche Médicale Wip1 inhibitor for the treatment of glomerular disease
WO2025162964A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
WO2025180665A1 (en) 2024-02-28 2025-09-04 Evotec International Gmbh Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
TW202602919A (zh) 2024-03-01 2026-01-16 德商百靈佳殷格翰國際股份有限公司 結締組織生長因子(ctgf)之抗體及其用途
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
WO2025202674A1 (en) 2024-03-27 2025-10-02 Institut National de la Santé et de la Recherche Médicale Langerhans cells targeting hiv-1 vaccines
EP4624494A1 (de) 2024-03-29 2025-10-01 Institut Curie Her2-einzeldomänenantikörper und verwendungen davon
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025215252A1 (en) 2024-04-12 2025-10-16 Ensocell Ltd Therapeutic agents and methods for targeting myeloid cell subtypes
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
EP4643858A1 (de) 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung von gebärmuttererkrankungen
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025229158A1 (en) 2024-05-01 2025-11-06 Commit Biologics Aps Antibodies and antibody constructs against cd38
WO2025229338A2 (en) 2024-05-03 2025-11-06 University Of Southampton An antibody or antibody fragment
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025242726A1 (en) 2024-05-21 2025-11-27 Onconick Ltd. Antibody binding to FGFR1 and conjugates comprising the same
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
EP4653460A1 (de) 2024-05-23 2025-11-26 Egle Therapeutics Il18r-agonist-antikörper und verwendungen davon
WO2025242910A1 (en) 2024-05-23 2025-11-27 Egle Therapeutics Il18r agonist antibodies and uses thereof
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof
WO2025248102A1 (en) 2024-05-31 2025-12-04 Institut National de la Santé et de la Recherche Médicale Tbk1 inhibitor for use in the treatment of vitiligo
WO2025255262A1 (en) 2024-06-05 2025-12-11 Inito Inc. Testosterone binding sequences
WO2025255349A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025255405A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Anti-fap antibodies and uses thereof
WO2025257151A1 (en) 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2025257715A1 (en) 2024-06-12 2025-12-18 Seagen Inc. Anti-ceacam5 antibodies, antibody-drug conjugates and methods of uses thereof
WO2025257365A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Adenosine a2a antagonists for the treatment of endometriosis
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
US20260103510A1 (en) 2024-06-17 2026-04-16 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
US20260001942A1 (en) 2024-06-21 2026-01-01 H. Lundbeck A/S Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
CA3258952A1 (en) 2024-06-27 2026-03-01 Janssen Biotech, Inc. Methods of treating ulcerative colitis with anti-il23 specific antibody
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026008785A1 (en) 2024-07-03 2026-01-08 Biotalys NV Agrochemical compositions
WO2026012976A1 (en) 2024-07-08 2026-01-15 Institut National de la Santé et de la Recherche Médicale Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
WO2026013052A1 (en) 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of treating familial adenomatous polyposis
WO2026013071A1 (en) 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Setdb1 inhibitor for use in the treatment of uveal melanoma
WO2026017820A1 (en) 2024-07-18 2026-01-22 Egle Therapeutics Fusion protein for cancer treatment
EP4681780A1 (de) 2024-07-18 2026-01-21 Egle Therapeutics Immunozytokine zur krebsbehandlung
WO2026030464A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026037839A2 (en) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Anti-fgfr4 molecules and uses thereof
WO2026041568A1 (en) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and dotam
WO2026044039A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Anti-cd73 antibodies, conjugates, and methods of use
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026052650A1 (en) 2024-09-05 2026-03-12 F. Hoffmann-La Roche Ag Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment
NL2038589B1 (en) 2024-09-05 2026-03-24 Academisch Ziekenhuis Leiden An antibody molecule
WO2026057679A1 (en) 2024-09-11 2026-03-19 Institut National de la Santé et de la Recherche Médicale Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)
WO2026072685A1 (en) 2024-09-25 2026-04-02 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2026068859A1 (en) 2024-09-30 2026-04-02 Université Libre de Bruxelles Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
WO2026073840A1 (en) 2024-10-01 2026-04-09 F. Hoffmann-La Roche Ag Antibodies that bind to cd3 and uses therefor
WO2026078060A1 (en) 2024-10-08 2026-04-16 Basf Se Tocopherol alkoxylates for biopolymer stabilization

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
DE3382317D1 (de) 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4806471A (en) 1982-09-16 1989-02-21 A/S Alfred Benzon Plasmids with conditional uncontrolled replication behavior
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5030565A (en) 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5126258A (en) 1984-09-07 1992-06-30 Scripps Clinic And Research Foundation Molecules with antibody combining sites that exhibit catalytic properties
JPS61104788A (ja) 1984-10-26 1986-05-23 Teijin Ltd 核酸塩基配列
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
ES8706823A1 (es) 1985-03-28 1987-06-16 Cetus Corp Un procedimiento para detectar la presencia o ausencia de al menos una secuencia especifica de acidos nucleicos en una muestra
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
SE458555B (sv) 1986-07-21 1989-04-10 Atte Heikkilae Linfaestanordning
US5229292A (en) 1986-07-28 1993-07-20 Stine Seed Farm, Inc. Biological control of insects using pseudomonas strains transformed with bacillus thuringiensis insect toxingene
JPS63152984A (ja) 1986-08-18 1988-06-25 Wakunaga Pharmaceut Co Ltd 抗緑膿菌ヒト型抗体のｌ鎖をコ−ドするｄｎａ
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
ATE87659T1 (de) * 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946786A (en) 1987-01-14 1990-08-07 President And Fellows Of Harvard College T7 DNA polymerase
DE3852304T3 (de) * 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
FR2629458B2 (fr) 1987-07-31 1991-08-09 Ire Celltarg Sa Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain
DE3732170C1 (de) 1987-09-24 1989-02-16 Bayer Ag Verfahren zur kontinuierlichen Extraktion von Polyamiden sowie dafuer geeignetes Extraktionsrohr
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
EP0368684B2 (de) * 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0404003A3 (de) 1989-06-19 1991-10-16 Xoma Corporation Chimäre Maus-Mensch-KM10-Antikörper, spezifisch für ein menschliches Tumorzellen-Antigen
US5023171A (en) 1989-08-10 1991-06-11 Mayo Foundation For Medical Education And Research Method for gene splicing by overlap extension using the polymerase chain reaction
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5229072A (en) 1992-02-03 1993-07-20 Liquid Carbonic Inc. Use of interhalogen compounds as a sterilizing agent
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
DK1712623T3 (da) * 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner

Also Published As

Publication number Publication date
US20040110941A2 (en) 2004-06-10
NO903059D0 (no) 1990-07-09
DK164790D0 (da) 1990-07-09
CA2002868A1 (en) 1990-05-11
AU4520189A (en) 1990-05-28
DE68913658T3 (de) 2005-07-21
FI903489A7 (fi) 1990-07-10
EP0368684B2 (de) 2004-09-29
ES2052027T3 (es) 1994-07-01
US7306907B2 (en) 2007-12-11
NO903059L (no) 1990-09-07
WO1990005144A1 (en) 1990-05-17
KR920700228A (ko) 1992-02-19
JPH03502801A (ja) 1991-06-27
KR0184860B1 (ko) 1999-04-01
EP0368684A1 (de) 1990-05-16
ES2052027T5 (es) 2005-04-16
FI903489A0 (fi) 1990-07-10
DK175392B1 (da) 2004-09-20
AU634186B2 (en) 1993-02-18
US6248516B1 (en) 2001-06-19
EP0368684B1 (de) 1994-03-09
JP2919890B2 (ja) 1999-07-19
US20030130496A1 (en) 2003-07-10
US20080299618A1 (en) 2008-12-04
US20030114659A1 (en) 2003-06-19
DK164790A (da) 1990-09-07
DE68913658T2 (de) 1994-09-08
CA2002868C (en) 2007-03-20
US6545142B1 (en) 2003-04-08
DE68913658D1 (de) 1994-04-14

Similar Documents

Publication Publication Date Title
DE68913658D1 (de) Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
DE68902375D1 (de) Verfahren zur vorsulfidierung von kohlenwasserstoffbehandlungskatalysatoren.
DE69626288D1 (de) Verbessrter prozess zur selektiven hydrierung von mehrfach ungesättigten verbindungen und isomerisierung von olefinen in kohlenwasserstoffströmen.
ATE466960T1 (de) Verwendung von nukleinsäureliganden in der durchflusszytometrie
ATE83801T1 (de) Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g.
ATE244506T1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
ATE199024T1 (de) Spezifisch und paarweise bindende verbindungen, mit eine kovalent, in der bindungsstelle gebunden chemischen gruppe; ihre herstellung und auswahl
DK0804237T3 (da) Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4
DE69603240D1 (de) Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
DK0597503T3 (da) ECK-receptorligander
DE69100456D1 (de) Verfahren zur Vorschwefelung von Kohlenwasserstoffbehandlungskatalysatoren.
ATE79270T1 (de) Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.
DE68905280D1 (de) Katalysatorzusammensetzung, verfahren zum cracken von nicht-aromatischen kohlenwasserstoffen und verfahren zur ionisierung von c-8-aromatischen kohlenwasserstoffen.
DE69007649D1 (de) Verfahren zur katalytischen Krackung von Kohlenwasserstoffen.
DE69308200D1 (de) Neuer Katalysator für Olefinpolymerisation, Verfahren zu seiner Herstellung und Verwendung zur Polymerisation von Olefinen
DE69432139D1 (de) Phosphin-Verbindungen, diese Phosphin-Verbindungen als ligande enthaltende Komplexe, Verfahren zur Herstellung von optisch-aktiven Aldehyden durch Mittel der Phosphin-Verbindungen oder des Komplexes
ATE24542T1 (de) Katalysator und verfahren zur katalytischen crackung.
ATE73111T1 (de) Verfahren zur herstellung von cyanwasserstoff.
DE50101047D1 (de) Verfahren zur herstellung von epoxiden durch oxidation von olefinen
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
DE3764168D1 (de) Verfahren zur katalytischen hydrobehandlung von kohlenwasserstoffen.
DE3764020D1 (de) Verfahren zur katalytischen hydrobehandlung von kohlenwasserstoffen.
DE3762843D1 (de) Verfahren zur behandlung von kohlenwasserstoffen mit durch halogenisierung stabilisierten katalysatoren aus der silicalit-oder tea-silikatreihe.
DE59508200D1 (de) Verfahren zur herstellung brom enthaltender aromatischer verbindungen, neue brom enthaltende verbindungen und ihre verwendung als zwischenprodukte bei der synthese von wirkstoffen
DE69000596D1 (de) Katalytische zusammensetzung und deren verwendung zur oligomerisation von monoolefinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time